PHILIPPINE BIDDING DOCUMENTS

for the

Supply and Delivery of Various Drugs and Medicines – Ampules/Vials for CY 2023 Framework Agreement

Project Reference No.: BAC1-2022-10-0068-A

End-User: **Property and Supply Division, Philippine General Hospital**

UPM – PHILIPPINE GENERAL HOSPITAL

Preface

These Philippine Bidding Documents (PBDs) for the procurement of Goods through Competitive Bidding have been prepared by the Government of the Philippines for use by any branch, constitutional commission or office, agency, department, bureau, office, or instrumentality of the Government of the Philippines, National Government Agencies, including Government-Owned and/or Controlled Corporations, Government Financing Institutions, State Universities and Colleges, and Local Government Unit. The procedures and practices presented in this document have been developed through broad experience, and are for mandatory use in projects that are financed in whole or in part by the Government of the Philippines or any foreign government/foreign or international financing institution in accordance with the provisions of the 2016 revised Implementing Rules and Regulations of Republic Act No. 9184.

The Bidding Documents shall clearly and adequately define, among others: (i) the objectives, scope, and expected outputs and/or results of the proposed contract or Framework Agreement, as the case may be; (ii) the eligibility requirements of Bidders; (iii) the expected contract or Framework Agreement duration, the estimated quantity in the case of procurement of goods, delivery schedule and/or time frame; and (iv) the obligations, duties, and/or functions of the winning bidder.

Care should be taken to check the relevance of the provisions of the PBDs against the requirements of the specific Goods to be procured. If duplication of a subject is inevitable in other sections of the document prepared by the Procuring Entity, care must be exercised to avoid contradictions between clauses dealing with the same matter.

Moreover, each section is prepared with notes intended only as information for the Procuring Entity or the person drafting the Bidding Documents. They shall not be included in the final documents. The following general directions should be observed when using the documents:

a. All the documents listed in the Table of Contents are normally required for the procurement of Goods. However, they should be adapted as necessary to the circumstances of the particular Procurement Project.

b. Specific details, such as the "*name of the Procuring Entity*" and "*address for bid submission*," should be furnished in the Instructions to Bidders, Bid Data Sheet, and Special Conditions of Contract. The final documents should contain neither blank spaces nor options.

c. This Preface and the footnotes or notes in italics included in the Invitation to Bid, Bid Data Sheet, General Conditions of Contract, Special Conditions of Contract, Schedule of Requirements, and Specifications are not part of the text of the final document, although they contain instructions that the Procuring Entity should strictly follow.

d. The cover should be modified as required to identify the Bidding Documents as to the Procurement Project, Project Identification Number, and Procuring Entity, in addition to the date of issue.

e. Modifications for specific Procurement Project details should be provided in the Special Conditions of Contract as amendments to the Conditions of Contract. For easy completion, whenever reference has to be made to specific clauses in the Bid Data Sheet or Special Conditions of Contract, these terms shall be printed in bold typeface on Sections I (Instructions to Bidders) and III (General Conditions of Contract), respectively.

f. For guidelines on the use of Bidding Forms and the procurement of Foreign-Assisted Projects, these will be covered by a separate issuance of the Government Procurement Policy Board.

Table of Contents

Glossary of Acronyms, Terms, and Abbreviations

ABC –Approved Budget for the Contract.

BAC – Bids and Awards Committee.

Bid – A signed offer or proposal to undertake a contract submitted by a bidder in response to and in consonance with the requirements of the bidding documents. Also referred to as *Proposal* and *Tender.* (2016 revised IRR, Section 5[c])

Bidder – Refers to a contractor, manufacturer, supplier, distributor and/or consultant who submits a bid in response to the requirements of the Bidding Documents. (2016 revised IRR, Section 5[d])

Bidding Documents – The documents issued by the Procuring Entity as the bases for bids, furnishing all information necessary for a prospective bidder to prepare a bid for the Goods, Infrastructure Projects, and/or Consulting Services required by the Procuring Entity. (2016 revised IRR, Section 5[e])

BIR – Bureau of Internal Revenue.

BSP – Bangko Sentral ng Pilipinas.

Consulting Services – Refer to services for Infrastructure Projects and other types of projects or activities of the GOP requiring adequate external technical and professional expertise that are beyond the capability and/or capacity of the GOP to undertake such as, but not limited to: (i) advisory and review services; (ii) pre-investment or feasibility studies; (iii) design; (iv) construction supervision; (v) management and related services; and (vi) other technical services or special studies. (2016 revised IRR, Section 5[i])

CDA - Cooperative Development Authority.

Contract – Refers to the agreement entered into between the Procuring Entity and the Supplier or Manufacturer or Distributor or Service Provider for procurement of Goods and Services; Contractor for Procurement of Infrastructure Projects; or Consultant or Consulting Firm for Procurement of Consulting Services; as the case may be, as recorded in the Contract Form signed by the parties, including all attachments and appendices thereto and all documents incorporated by reference therein.

CIF – Cost Insurance and Freight.

CIP – Carriage and Insurance Paid.

CPI – Consumer Price Index.

DDP – Refers to the quoted price of the Goods, which means "delivered duty paid."

DTI – Department of Trade and Industry.

EXW – Ex works.

FCA – "Free Carrier" shipping point.

FOB – "Free on Board" shipping point.

Foreign-funded Procurement or Foreign-Assisted Project–Refers to procurement whose funding source is from a foreign government, foreign or international financing institution as specified in the Treaty or International or Executive Agreement. (2016 revised IRR, Section 5[b]).

Framework Agreement – Refers to a written agreement between a procuring entity and a supplier or service provider that identifies the terms and conditions, under which specific purchases, otherwise known as "Call-Offs," are made for the duration of the agreement. It is in the nature of an option contract between the procuring entity and the bidder(s) granting the procuring entity the option to either place an order for any of the goods or services identified in the Framework Agreement List or not buy at all, within a minimum period of one (1) year to a maximum period of three (3) years. (GPPB Resolution No. 27-2019)

GFI – Government Financial Institution.

GOCC –Government-owned and/or –controlled corporation.

Goods – Refer to all items, supplies, materials and general support services, except Consulting Services and Infrastructure Projects, which may be needed in the transaction of public businesses or in the pursuit of any government undertaking, project or activity, whether in the nature of equipment, furniture, stationery, materials for construction, or personal property of any kind, including non-personal or contractual services such as the repair and maintenance of equipment and furniture, as well as trucking, hauling, janitorial, security, and related or analogous services, as well as procurement of materials and supplies provided by the Procuring Entity for such services. The term "related" or "analogous services" shall include, but is not limited to, lease or purchase of office space, media advertisements, health maintenance services, and other services essential to the operation of the Procuring Entity. (2016 revised IRR, Section 5[r])

GOP – Government of the Philippines.

GPPB – Government Procurement Policy Board.

INCOTERMS – International Commercial Terms.

Infrastructure Projects – Include the construction, improvement, rehabilitation, demolition, repair, restoration or maintenance of roads and bridges, railways, airports, seaports, communication facilities, civil works components of information technology projects, irrigation, flood control and drainage, water supply, sanitation, sewerage and solid waste management systems, shore protection, energy/power and electrification facilities, national

buildings, school buildings, hospital buildings, and other related construction projects of the government. Also referred to as *civil works or works*. (2016 revised IRR, Section 5[u])

LGUs – Local Government Units.

NFCC – Net Financial Contracting Capacity.

NGA – National Government Agency.

PhilGEPS - Philippine Government Electronic Procurement System.

Procurement Project – refers to a specific or identified procurement covering goods, infrastructure project or consulting services. A Procurement Project shall be described, detailed, and scheduled in the Project Procurement Management Plan prepared by the agency which shall be consolidated in the procuring entity's Annual Procurement Plan. (GPPB Circular No. 06-2019 dated 17 July 2019)

PSA – Philippine Statistics Authority.

SEC – Securities and Exchange Commission.

SLCC – Single Largest Completed Contract.

Supplier – refers to a citizen, or any corporate body or commercial company duly organized and registered under the laws where it is established, habitually established in business and engaged in the manufacture or sale of the merchandise or performance of the general services covered by his bid. (Item 3.8 of GPPB Resolution No. 13-2019, dated 23 May 2019). Supplier as used in these Bidding Documents may likewise refer to a distributor, manufacturer, contractor, or consultant.

UN – United Nations.

Section I. Invitation to Bid

Notes on the Invitation to Bid

The Invitation to Bid (IB) provides information that enables potential Bidders to decide whether to participate in the procurement at hand. The IB shall be posted in accordance with Section 21.2 of the 2016 revised IRR of RA No. 9184.

Apart from the essential items listed in the Bidding Documents, the IB should also indicate the following:

a. The date of availability of the Bidding Documents, which shall be from the time the IB is first advertised/posted until the deadline for the submission and receipt of bids;

b. The place where the Bidding Documents may be acquired or the website where it may be downloaded;

c. The deadline for the submission and receipt of bids; and

d. Any important bid evaluation criteria (*e.g.*, the application of a margin of preference in bid evaluation).

The IB should be incorporated in the Bidding Documents. The information contained in the IB must conform to the Bidding Documents and in particular to the relevant information in the Bid Data Sheet.

University of the Philippines
The Health Sciences Center
BIDS & AWARDS COMMITTEE 1
BAC Office, PGH Compound
Taft Avenue, Manila
Tel. No. 554-8400 local 3014 / 3015

INVITATION TO BID FOR
Supply and Delivery of Drugs and Medicines – Ampules and Vials for CY2023 (Framework Agreement)

1. The ***University of the Philippines Manila – Philippine General Hospital (UPM-PGH)***, using a *single-year* for a duration of *one (1) year* Framework Agreement, through the *General Appropriations Act CY 2022* intends to apply the sum of **Six Hundred Twenty Five Million Seven Hundred Twelve Thousand One Hundred Sixty Four Pesos & 01/100 (PhP625,712,164.01) inclusive of all taxes, such as, but not limited to, value added tax (VAT), income tax, local taxes, and other fiscal levies**, *being the ABC to payments under the contract for each item. Bids received in excess of the total cost per item shall be automatically rejected.*

2. The ***University of the Philippines Manila – Philippine General Hospital (UPM-PGH)*** now invites bids for ***Supply and Delivery of Various Drugs and Medicines – Ampules and Vials for CY2023 (Framework Agreement).*** Delivery of the Goods will be on staggered basis. Bidders should have completed, within two (2) years from the date of submission and receipt of bids, a contract similar to the Project. The description of an eligible bidder is contained in the Bidding Documents, particularly, in Section II (Instructions to Bidders).

3. Bidding will be conducted through open competitive bidding procedures using a non-discretionary "*pass/fail*" criterion as specified in the 2016 revised Implementing Rules and Regulations (IRR) of Republic Act (RA) No. 9184

   Bidding is restricted to Filipino citizens/sole proprietorships, partnerships, or organizations with at least sixty percent (60%) interest or outstanding capital stock belonging to citizens of the Philippines, and to citizens or organizations of a country the laws or regulations of which grant similar rights or privileges to Filipino citizens, pursuant to RA No. 5183.

4. Prospective Bidders may obtain further information from UPM-PGH BAC Secretariat and inspect the Bidding Documents at the address given below during office hours from8:00AM to 4:30PM.

5. A complete set of Bidding Documents may be acquired by interested Bidders on **18 November 2022** from the given address and website(s) below upon payment of the applicable fee for the Bidding Documents, pursuant to the latest Guidelines issued by the GPPB, in the amount of ***(to be determined upon issuance of bid documents)***. The Procuring Entity shall allow the bidder to present its proof of payment for the fees in person, or through electronic means.

6. The **UPM-PGH** will hold a **Pre-Bid Conference** on **29 November 2022, 9:30 AM** at **Bids and Awards Committee 1(BAC1) Office, PGH Compound Taft Avenue Manila** and/or through video conferencing or webcasting *via* ***ZOOM***, which shall be open to prospective bidders.

7. Bids must be duly received by the BAC Secretariat through manual submission at the office address indicated below, on or before **9:00AM, 13 December 2022**. Late bids shall not be accepted.

8. All Bids must be accompanied by a bid security in any of the acceptable forms and in the amount stated in **ITB** Clause 14.

9. Bid opening shall be on **9:30AM, 13 December 2022** at the given address below. Bids will be opened in the presence of the bidders' representatives who choose to attend the activity.

10. The UPM-PGH reserves the right to reject any and all bids, declare a failure of bidding, or not award the contract at any time prior to contract award in accordance with Sections35.6 and 41 of the 2016 revised IRR of RA No. 9184, without thereby incurring any liability to the affected bidder or bidders.

11. For further information, please refer to:

    BAC 1 Secretariat
    UP-Philippine General Hospital
    PGH Compound, Taft Avenue, Manila
    Telephone No.: 8-554-8400 local 3014/3015
    e-Mail Address: bac1pgh.upm@up.edu.ph

12. You may visit the following websites:

    For downloading of Bidding Documents: *www.philgeps.gov.ph and https://bidsandawards.up.edu.ph*

Dean CHARLOTTE M. CHIONG, MD, PhD
Chairperson

Section II. Instructions to Bidders

Notes on the Instructions to Bidders

This Section on the Instruction to Bidders (ITB) provides the information necessary for bidders to prepare responsive bids, in accordance with the requirements of the ***University of the Philippines Manila – Philippine General Hospital***. It also provides information on bid submission, eligibility check, opening and evaluation of bids, post-qualification, and on the award of contract.

1. Scope of Bid

The Procuring Entity, UPM-PGH wishes to receive Bids for the ***Supply and Delivery of Various Drugs and Medicines – Ampules/Vials for CY 2023*** under a Framework Agreement, with identification number ***BAC1-2022-10-0068-A***

The Procurement Project (referred to herein as "Project") is composed of *one hundred eighty nine (189) items*, the details of which are described in Section VII (Technical Specifications).

2. Funding Information

2.1. The GOP through the source of funding as indicated below for ***General Appropriations Act CY 2023*** in the amount of **Six Hundred Twenty Five Million Seven Hundred Twelve Thousand One Hundred Sixty Four Pesos & 01/100 (Ph625,712,164.01)**

2.2. The source of funding is:

a. NGA, the National Expenditure Program.

3. Bidding Requirements

The Bidding for the Project shall be governed by all the provisions of RA No. 9184 and its 2016 revised IRR, including its Generic Procurement Manuals and associated policies, rules and regulations as the primary source thereof, while the herein clauses shall serve as the secondary source thereof.

Any amendments made to the IRR and other GPPB issuances shall be applicable only to the ongoing posting, advertisement, or **ITB** by the BAC through the issuance of a supplemental or bid bulletin.

The Bidder, by the act of submitting its Bid, shall be deemed to have verified and accepted the general requirements of this Project, including other factors that may affect the cost, duration and execution or implementation of the contract, project, or work and examine all instructions, forms, terms, and project requirements in the Bidding Documents.

4. Corrupt, Fraudulent, Collusive, and Coercive Practices

The Procuring Entity, as well as the Bidders and Suppliers, shall observe the highest standard of ethics during the procurement and execution of the contract. They or through an agent shall not engage in corrupt, fraudulent, collusive, coercive, and obstructive practices defined under Annex "I" of the 2016 revised IRR of RA No. 9184 or other integrity violations in competing for the Project.

5. Eligible Bidders

5.1. Only Bids of Bidders found to be legally, technically, and financially capable will be evaluated.

5.2. Foreign ownership exceeding those allowed under the rules may participate pursuant to:

i. When a Treaty or International or Executive Agreement as provided in Section 4 of the RA No. 9184 and its 2016 revised IRR allow foreign bidders to participate;

ii. Citizens, corporations, or associations of a country, included in the list issued by the GPPB, the laws or regulations of which grant reciprocal rights or privileges to citizens, corporations, or associations of the Philippines;

iii. When the Goods sought to be procured are not available from local suppliers; or

iv. When there is a need to prevent situations that defeat competition or restrain trade.

5.3. Pursuant to Section 23.4.1.3 of the 2016 revised IRR of RA No.9184, the Bidder shall have an SLCC that is at least one (1) contract similar to the Project the value of which, adjusted to current prices using the PSA's CPI, must be at least equivalent to:

a. For the procurement of Non-expendable Supplies and Services: The Bidder must have completed a single contract that is similar to this Project, equivalent to at least fifty percent (50%) of the ABC.

b. For the procurement of Expendable Supplies: The Bidder must have completed a single contract that is similar to this Project, equivalent to at least twenty-five percent (25%) of the ABC.

c. For procurement where the Procuring Entity has determined, after the conduct of market research, that imposition of either (a) or (b) will likely result to failure of bidding or monopoly that will defeat the purpose of public bidding: the Bidder should comply with the following requirements: [*Select either failure or monopoly of bidding based on market research conducted*]

i. Completed at least two (2) similar contracts, the aggregate amount of which should be equivalent to at least *fifty percent (50%) in the case of non-expendable supplies and services or twenty-five percent (25%) in the case of expendable supplies*] of the ABC for this Project; and

ii. The largest of these similar contracts must be equivalent to at least half of the percentage of the ABC as required above.

5.4. The Bidders shall comply with the eligibility criteria under Section 23.4.1 of the 2016 IRR of RA No. 9184.

6. Origin of Goods

There is no restriction on the origin of goods other than those prohibited by a decision of the UN Security Council taken under Chapter VII of the Charter of the UN, subject to Domestic Preference requirements under **ITB** Clause 18.

7. Subcontracts

7.1. The Bidder may subcontract portions of the Project to the extent allowed by the Procuring Entity as stated herein, but in no case more than twenty percent (20%) of the Project.

The Procuring Entity has prescribed that:

a. Subcontracting is not allowed.

8. Pre-Bid Conference

The Procuring Entity will hold a pre-bid conference for this Project on the specified date and time and either at its physical address at the **BAC Conference Room, BAC Office PGH Compound Taft Avenue Ermita Manila** and/or through **ZOOM** as indicated in paragraph 6 of the **IB.**

9. Clarification and Amendment of Bidding Documents

Prospective bidders may request for clarification on and/or interpretation of any part of the Bidding Documents. Such requests must be in writing and received by the Procuring Entity, either at its given address or through electronic mail indicated in the **IB**, at least ten (10) calendar days before the deadline set for the submission and receipt of Bids.

10. Documents comprising the Bid: Eligibility and Technical Components

10.1. The first envelope shall contain the eligibility and technical documents of the Bid as specified in **Section VIII (Checklist of Technical and Financial Documents)**.

10.2. The Bidder's SLCC as indicated in **ITB** Clause5.3 should have been completed within prior to the deadline for the submission and receipt of bids.

10.3. If the eligibility requirements or statements, the bids, and all other documents for submission to the BAC are in foreign language other than English, it must be accompanied by a translation in English, which shall be authenticated by the appropriate Philippine foreign service establishment, post, or the equivalent office having jurisdiction over the foreign bidder's affairs in the Philippines. Similar to the required authentication above, for Contracting Parties to the Apostille Convention, only the translated documents shall be authenticated through an apostille pursuant to GPPB Resolution No. 13-2019 dated 23 May 2019. The English translation shall govern, for purposes of interpretation of the bid.

11. Documents comprising the Bid: Financial Component

11.1. The second bid envelope shall contain the financial documents for the Bid as specified in **Section VIII (Checklist of Technical and Financial Documents)**.

11.2. If the Bidder claims preference as a Domestic Bidder or Domestic Entity, a certification issued by DTI shall be provided by the Bidder in accordance with Section 43.1.3 of the 2016 revised IRR of RA No. 9184.

11.3. Any bid exceeding the ABC indicated in paragraph 1 of the **IB** shall not be accepted.

11.4. For Foreign-funded Procurement, a ceiling may be applied to bid prices provided the conditions are met under Section 31.2 of the 2016 revised IRR of RA No. 9184.

11.5. Financial proposals for single or multi-year Framework Agreement shall be submitted before the deadline of submission of bids as prescribed in the **IB**. For multi-year Framework Agreement, evaluation of the financial proposal during this stage is for purposes of determining eligibility and whether or not such financial proposal is within the ABC.

12. Bid Prices

12.1. Prices indicated on the Price Schedule shall be entered separately in the following manner:

a. For Goods offered from within the Procuring Entity's country:

i. The price of the Goods quoted EXW (ex-works, ex-factory, ex-warehouse, ex-showroom, or off-the-shelf, as applicable);

ii. The cost of all customs duties and sales and other taxes already paid or payable;

iii. The cost of transportation, insurance, and other costs incidental to delivery of the Goods to their final destination; and

iv. The price of other (incidental) services, if any, listed in e.

b. For Goods offered from abroad:

i. Unless otherwise stated in the **BDS**, the price of the Goods shall be quoted delivered duty paid (DDP) with the place of destination in the Philippines as specified in the **BDS**. In quoting the price, the Bidder shall be free to use transportation through carriers registered in any eligible country. Similarly, the Bidder may obtain insurance services from any eligible source country.

ii. The price of other (incidental) services, if any, as listed in **Section VII (Technical Specifications).**

12.2. For Framework Agreement, the following should also apply in addition to Clause 12.1:

a. For a single year Framework Agreement, the prices quoted by the Bidder shall be fixed during the Bidder's performance of the contract and not subject to variation or escalation on any account. Price schedules required under Clause 12.1 shall be submitted with the bidding documents.

b. For a multi-year Framework Agreement, the prices quoted by the Bidder during submission of eligibility documents shall be the ceiling and the price quoted during mini-competition must not exceed the initial price offer. The price quoted during call for mini-competition shall be fixed during the Bidder's performance of that Call-off and not subject to variation or escalation on any account. Price schedules required under Clause 12.1 shall be submitted with the bidding documents.

13. Bid and Payment Currencies

13.1. For Goods that the Bidder will supply from outside the Philippines, the bid prices may be quoted in the local currency or tradeable currency accepted by the BSP at the discretion of the Bidder. However, for purposes of bid evaluation, Bids denominated in foreign currencies, shall be converted to Philippine currency based on the exchange rate as published in the BSP reference rate bulletin on the day of the bid opening.

13.2. Payment of the contract price shall be made in:
a. Philippine Pesos.

14. Bid Security

14.1. The Bidder shall submit a Bid Securing Declaration[1] or any form of Bid Security in the amount indicated+ in the **BDS**, which shall be not less than the percentage of the ABC in accordance with the schedule in the **BDS**.

14.2. The Bid and bid security shall be valid until ***one hundred twenty (120) calendar days from the date of opening of bids.*** Any Bid not accompanied by an acceptable bid security shall be rejected by the Procuring Entity as non-responsive.

14.3. In the case of Framework Agreement, other than the grounds for forfeiture under the 2016 revised IRR, the bid security may also be forfeited if the successful bidder fails to sign the Framework Agreement, or fails to furnish the performance security or performance securing declaration. Without prejudice on its forfeiture, bid securities shall be returned only after the posting of performance security or performance securing declaration, as the case may be, by the winning Bidder or compliant Bidders and the signing of the Framework Agreement.

[1] In the case of Framework Agreement, the undertaking shall refer to entering into contract with the Procuring Entity and furnishing of the performance security or the performance securing declaration within ten (10) calendar days from receipt of Notice to Execute Framework Agreement.

15. Sealing and Marking of Bids

Each Bidder shall submit one copy of the first and second components of its Bid.

The Procuring Entity may request additional hard copies and/or electronic copies of the Bid. However, failure of the Bidders to comply with the said request shall not be a ground for disqualification.

If the Procuring Entity allows the submission of bids through online submission or any other electronic means, the Bidder shall submit an electronic copy of its Bid, which must be digitally signed. An electronic copy that cannot be opened or is corrupted shall be considered non-responsive and, thus, automatically disqualified.

16. Deadline for Submission of Bids

16.1. The Bidders shall submit on the specified date and time and either at its physical address or through online submission as indicated in paragraph 7 of the **IB.**

16.2. For multi-year Framework Agreement, the submission of bids shall be for the initial evaluation of their technical and financial eligibility. Thereafter, those declared eligible during the said initial eligibility evaluation and entered into a Framework Agreement with the Procuring Entity shall submit anew their best financial offer at the address and on or before the date and time indicated in the Call for each mini-competition.

17. Opening and Preliminary Examination of Bids

17.1. The BAC shall open the Bids in public at the time, on the date, and at the place specified in paragraph 9 of the **IB**. The Bidders' representatives who are present shall sign a register evidencing their attendance. In case videoconferencing, webcasting or other similar technologies will be used, attendance of participants shall likewise be recorded by the BAC Secretariat.

In case the Bids cannot be opened as scheduled due to justifiable reasons, the rescheduling requirements under Section 29 of the 2016 revised IRR of RA No. 9184 shall prevail.

17.2. The preliminary examination of bids shall be governed by Section 30 of the 2016 revised IRR of RA No. 9184.

18. Domestic Preference

18.1. The Procuring Entity will grant a margin of preference for the purpose of comparison of Bids in accordance with Section 43.1.2 of the 2016 revised IRR of RA No. 9184.

18.2. For multi-year Framework Agreement, determination of margin of preference shall be conducted every call for Mini-Competition.

19. Detailed Evaluation and Comparison of Bids

19.1. The Procuring BAC shall immediately conduct a detailed evaluation of all Bids rated "*passed*," using non-discretionary pass/fail criteria. The BAC shall consider the conditions in the evaluation of Bids under Section 32.2 of the 2016 revised IRR of RA No. 9184.

a. In the case of single-year Framework Agreement, the Lowest Calculated Bid shall be determined outright after the detailed evaluation;

b. For multi-year Framework Agreement, the determination of the eligibility and the compliance of bidders with the technical and financial aspects of the projects shall be initially made by the BAC, in accordance with Item 7.4.2 of the Guidelines on the Use of Framework Agreement.

19.2. If the Project allows partial bids, bidders may submit a proposal on any of the lots or items, and evaluation will be undertaken on a per lot or item basis, as the case maybe. In this case, the Bid Security as required by **ITB** Clause 15 shall be submitted for each lot or item separately.

19.3. The descriptions of the lots or items shall be indicated in **Section VII (Technical Specifications)**, although the ABCs of these lots or items are indicated in the **BDS** for purposes of the NFCC computation pursuant to Section 23.4.2.6 of the 2016 revised IRR of RA No. 9184. The NFCC must be sufficient for the total of the ABCs for all the lots or items participated in by the prospective Bidder.

19.4. The Project shall be awarded as follows:

Option 1 – One Project having several items that shall be awarded as one contract.

19.5. Except for bidders submitting a committed Line of Credit from a Universal or Commercial Bank in lieu of its NFCC computation, all Bids must include the NFCC computation pursuant to Section 23.4.1.4 of the 2016 revised IRR of RA No. 9184, which must be sufficient for the total of the ABCs for all the lots or items participated in by the prospective Bidder. For bidders submitting the committed Line of Credit, it must be at least equal to ten percent (10%) of the ABCs for all the lots or items participated in by the prospective Bidder.

20. Post-Qualification

20.1. For multi-year Framework Agreement, all bidders initially determined to be eligible and financially compliant shall be subject to initial post-qualification. The BAC shall then recommend the execution of a Framework Agreement among all eligible, technically and financially compliant bidders and the Procuring Entity and shall be issued by HoPE a Notice to Execute Framework Agreement. The determination of the Lowest Calculated Bid (LCB) shall not be performed by the BAC until a Mini-Competition is conducted among the bidders who executed a Framework Agreement. When a Call for Mini-Competition is made, the BAC shall allow the bidders to submit their best

financial proposals on such pre-scheduled date, time and place to determine the bidder with the LCB.

20.2. Within a non-extendible period of five (5) calendar days from receipt by the Bidder of the notice from the BAC that it submitted the Lowest Calculated Bid, or in the case of multi-year Framework Agreement, that it is one of the eligible bidders who have submitted bids that are found to be technically and financially compliant,}the Bidder shall submit its latest income and business tax returns filed and paid through the BIR Electronic Filing and Payment System (eFPS) and other appropriate licenses and permits required by law and stated in the **BDS**. For every mini-competition in Framework Agreement, the LCB shall likewise submit the required documents for final Post Qualification.}

21. Signing of the Contract

21.1. The documents required in Section 37.2 of the 2016 revised IRR of RA No. 9184 shall form part of the Contract. Additional Contract documents are indicated in the **BDS**.

21.2. At the same time as the Procuring Entity notifies the successful Bidder that its bid has been accepted, the Procuring Entity shall send the Framework Agreement Form to the Bidder, which contract has been provided in the Bidding Documents, incorporating therein all agreements between the parties.

21.3. Within ten (10) calendar days from receipt of the Notice to Execute Framework Agreement with the Procuring Entity, the successful Bidder or its duly authorized representative shall formally enter into a Framework Agreement with the procuring entity for an amount of One Peso to be paid to the procuring entity as a consideration for the option granted by the procuring entity to procure the items in the Framework Agreement List when the need arises.

21.4. The Procuring Entity shall enter into a Framework Agreement with the successful Bidder within the same ten (10) calendar day period provided that all the documentary requirements are complied with.

21.5. The following documents shall form part of the Framework Agreement:

a. Framework Agreement Form;
b. Bidding Documents;
c. Call-offs;
d. Winning bidder's bid, including the Technical and Financial Proposals, and all other documents/statements submitted (*e.g.*, bidder's response to request for clarifications on the bid), including corrections to the bid, if any, resulting from the Procuring Entity's bid evaluation;
e. Performance Security or Performance Securing Declaration, as the case may be;
f. Notice to Execute Framework Agreement; and
g. Other contract documents that may be required by existing laws and/or specified in the **BDS**.

Section III. Bid Data Sheet

Notes on the Bid Data Sheet

The Bid Data Sheet (BDS) consists of provisions that supplement, amend, or specify in detail, information, or requirements included in the ITB found in Section II, which are specific to each procurement.

This Section is intended to assist the ***University of the Philippines Manila – Philippine General Hospital*** in providing the specific information in relation to corresponding clauses in the ITB and has to be prepared for each specific procurement.

The ***University of the Philippines Manila – Philippine General Hospital*** should specify in the BDS information and requirements specific to the circumstances of the ***University of the Philippines Manila – Philippine General Hospital***, the processing of the procurement, and the bid evaluation criteria that will apply to the Bids. In preparing the BDS, the following aspects should be checked:

a. Information that specifies and complements provisions of the ITB must be incorporated.

b. Amendments and/or supplements, if any, to provisions of the ITB as necessitated by the circumstances of the specific procurement, must also be incorporated.

Bid Data Sheet

<table>
<tr><th>ITB Clause</th><th colspan="5"></th></tr>
<tr><td>5.3</td><td colspan="5">For this purpose, contracts similar to the Project shall be:

a. Drugs and Medicines

b. completed within two (2) years prior to the deadline for the submission and receipt of bids.</td></tr>
<tr><td>7.1</td><td colspan="5">Subcontracting is not allowed</td></tr>
<tr><td>12</td><td colspan="5">The price of the Goods shall be quoted DDP University of the Philippines Manila – Philippine General Hospital for the applicable International Commercial Terms (INCOTERMS) for this Project.</td></tr>
<tr><td>14.1</td><td colspan="5">The bid security shall be in the form of a Bid Securing Declaration, or any of the following forms and amounts:</td></tr>
<tr><td></td><td colspan="5">a. The amount of not less than the amount equivalent to two percent (2%) of ABC, if bid security is in cash, cashier’s/manager’s check, bank draft/guarantee or irrevocable letter of credit; or</td></tr>
<tr><td></td><td colspan="5">b. The amount of not less than the amount equivalent to five percent (5%) of ABC if bid security is in Surety Bond.</td></tr>
<tr><td>19.3</td><td>ITEM NO.</td><td>QTY</td><td>UOM</td><td>ITEM DESCRIPTION (AGENCY’s REQUIREMENTS)</td><td>ABC PER UNIT (PHP)</td></tr>
<tr><td></td><td>1</td><td>720</td><td>pc</td><td>Acetylcysteine 200mg/mL, 25mL vial/bottle (IV infusion)</td><td>1,813.00</td></tr>
<tr><td></td><td>2</td><td>4,800</td><td>pc</td><td>Aciclovir 25mg/mL, 10mL vial (IV infusion)</td><td>977.43</td></tr>
<tr><td></td><td>3</td><td>3,144</td><td>pc</td><td>Albumin Human 20%, 50mL bottle (IV, IV infusion)</td><td>2,100.00</td></tr>
<tr><td></td><td>4</td><td>1,114</td><td>pc</td><td>Adenosine 3 mg/mL, 2 mL vial (IV)</td><td>1,960.00</td></tr>
<tr><td></td><td>5</td><td>12,000</td><td>pc</td><td>Amikacin sulfate 125mg/mL , 2mL ampule/vial (IM, IV)</td><td>386.00</td></tr>
<tr><td></td><td>6</td><td>14,928</td><td>pc</td><td>Amikacin sulfate 250mg/mL , 2mL ampule/vial (IM, IV)</td><td>97.44</td></tr>
<tr><td></td><td>7</td><td>1,200</td><td>pc</td><td>Aminophylline (theophylline ethylenediamine) 25 mg/mL, 10 mL ampul (IV)</td><td>45.00</td></tr>
<tr><td></td><td>8</td><td>5,750</td><td>pc</td><td>Amiodarone hydrochloride 50 mg/mL, 3 mL ampul (IV)</td><td>448.00</td></tr>
<tr><td></td><td>9</td><td>720</td><td>pc</td><td>Amphotericin B non lipid complex 50mg lyophilized powder, vial (IV infusion)</td><td>2,448.00</td></tr>
</table>

	10	1,440	pc	Amphotericin B Lipid Complex (as cholesteryl complex, colloidal dispersion) 50 mg vial (IV infusion)	13,499.00
	11	24,000	pc	Ampicillin + Sulbactam 1000 mg ampicillin + 500 mg sulbactam (IM, IV) (as sodium salt) per vial	310.00
	12	25,320	pc	Ampicillin + Sulbactam 500 mg ampicillin + 250 mg sulbactam (IM, IV) (as sodium salt) per vial	210.00
	13	12,000	pc	Ampicillin sodium 250mg vial (IM, IV)	37.85
	14	13,320	pc	Ampicillin sodium 500mg vial (IM, IV)	54.00
	15	16,380	pc	Atracurium besilate 10mg/mL, 2.5mL ampule (IV)	230.00
	16	20,170	pc	Atropine sulfate 1mg/mL, 1 mL ampul (IM, IV, SC)	18.69
	17	2,400	pc	Azithromycin 500 mg powder, vial (IV infusion) (as base*/as dihydrate)	540.00
	18	2,400	pc	Aztreonam 1g powder for injection (IV, IV Infusion)	1,142.35
	19	13	pc	Basiliximab 20 mg vial (IV infusion)	60,445.83
	20	240	pc	Beractant 25 mg/ml suspension, 8mL Intratracheal administration vial	17,354.18
	21	240	pc	Beractant 25 mg/mL suspension, 4 mL Intratracheal administration vial	11,070.25
	22	360	pc	Bleomycin sulfate powder, 15 IU ampul/vial (IM,IV)	2,750.00
	23	8,280	pc	Bupivacaine Hydrochloride 0.5% 4 mL ampul (spinal) with 8% dextrose	457.00
	24	18,000	pc	Bupivacaine Hydrochloride 0.5%, 10mL ampul/vial (local infiltration)	341.78
	25	2,655	pc	Butorphanol tartrate 2 mg/mL, 1 mL ampul/vial (IM, IV)	508.93
	26	6,940	pc	Calcium folinate (leucovorin Ca) 10mg/mL, 5mL ampule/vial (IM, IV)	180.00
	27	25,470	pc	Calcium Gluconate 10%, 10 mL ampul/vial (IV)	164.00
	28	6,120	pc	Carbetocin 100 mcg/mL, 1 mL ampule/vial, solution for Injection (IV)	1,200.00
	29	312	pc	Carboprost 250 mcg/mL solution for injection, 1 mL ampule/vial	500.00
	30	1,575	pc	Carboplatin 10mg/mL, 15mL vial (IV)	890.00
	31	2,450	pc	Carboplatin 10mg/mL, 45mL vial (IV)	3,900.00
	32	19,680	pc	Cefazolin sodium 1gm vial (IM, IV)	215.00
	33	4,800	pc	Cefepime Hydrochloride 1gm vial (IM, IV)	312.50

	34	2,400	pc	Cefepime Hydrochloride 2gms vial (IM, IV)	441.10
	35	2,400	pc	Cefotaxime sodium 500 mg vial + 2 mL diluent (IM, IV)	740.50
	36	17,748	pc	Ceftazidime pentahydrate 1gm vial (IM, IV)	210.00
	37	25,320	pc	Ceftriaxone disodium/sodium 1gm vial + 10mL diluent (IV)	368.00
	38	19,680	pc	Cefuroxime sodium 750mg vial (IM, IV)	90.00
	39	7,200	pc	Ciprofloxacin lactate 2mg/mL, 100mL vial (IV infusion)	241.08
	40	325	pc	Cisplatin 1mg/mL, 10mL vial (IV)	187.00
	41	1,500	pc	Cisplatin 1mg/mL, 50mL vial (IV)	450.00
	42	25,320	pc	Clindamycin phosphate 150mg/mL, 2mL ampule/vial (IM, IV)	198.00
	43	24,000	pc	Clindamycin phosphate 150mg/mL, 4mL ampule (IM, IV)	370.00
	44	1,090	pc	Colistin 2,000,000 IU lyophilized powder for injection (IV infusion)	2,232.14
	45	2,715	pc	Cyclophosphamide 500mg vial powder (IV)	220.00
	46	2,715	pc	Cyclophosphamide 1gm vial powder (IV)	350.00
	47	3,015	pc	Cytarabine 100 mg/mL solution for injection, 1 mL	130.00
	48	2,115	pc	Cytarabine 100 mg/mL solution for injection, 5 mL	376.00
	49	2,115	pc	Cytarabine 100 mg/mL solution for injection, 10 mL	1,607.14
	50	600	pc	Dacarbazine powder, 200mg vial (IV, IV infusion)	714.30
	51	440	pc	Dactinomycin powder, 500 micrograms vial (IV)	440.00
	52	396	pc	Dantrolene Sodium 20 mg (with mannitol 3g)/vial (for reconstitution with 60 mL sterile water for injection) (IV) (With Compassionate Special Permit)	16,170.00
	53	2,460	pc	Deferoxamine mesilate powder, 500 mg vial (IM, IV infusion, SC)	183.32
	54	56,920	pc	Dexamethasone sodium phoshate 4 mg/mL, 2 mL ampul/vial (IM, IV)	69.00
	55	53,400	pc	Dexamethasone sodium phoshate 5mg/mL, 1mL ampule (IM, IV)	67.23
	56	990	pc	Diazepam 5 mg/mL, 2 mL ampul (IM, IV) (With PDEA Permit)	138.22
	57	984	pc	Digoxin 250 micrograms/mL, 2 mL ampul (IM, IV)	310.00

	58	20,770	pc	Diphenhydramine Hydrochloride 50 mg/mL, 1 mL ampul (IM, IV)	98.00
	59	3,726	pc	Dobutamine Hydrochloride 50mg/mL, 5ml ampule (IV infusion)	490.00
	60	1,500	pc	Docetaxel anhydrous 20 mg/0.5 mL, 0.5 mL vial (IV infusion)	1,105.00
	61	750	pc	Docetaxel anhydrous 40 mg/mL, 2 mL vial (IV infusion)	3,220.00
	62	3,720	pc	Dopamine Hydrochloride 40mg/mL 5mL vial/ampule (IV)	234.50
	63	3,750	pc	Doxorubicin Hydrochloride powder, 50mg vial or 2mg/mL, 25mL vial (IV)	500.20
	64	24,300	pc	Enoxaparin sodium 100mg/mL, 0.4mL pre-filled syringe (SC)	794.00
	65	15,000	pc	Enoxaparin sodium 100mg/mL, 0.6mL pre-filled syringe (SC)	778.00
	66	3,300	pc	Ephedrine sulfate 50 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	86.50
	67	64,100	pc	Epinephrine Hydrochloride 1mg/mL, 1mL ampule (IV, IM, SC)	80.00
	68	75	pc	Epirubicin (as hydrochloride) powder, 50mg vial (IV)	2,943.33
	69	384	pc	Epoetin alfa (recombinant human erythropoetin) 10,000 IU/mL, pre-filled syringe (IV, SC)	1,458.00
	70	3,000	pc	Epoetin alfa (recombinant human erythropoetin) 4000 IU/0.4 mL, pre-filled syringe (IV, SC)	950.00
	71	480	pc	Epoetin alfa (recombinant human erythropoietin) 2000 IU/0.5 mL, pre-filled syringe (IV, SC)	542.86
	72	480	pc	Epoetin Beta (recombinant erythropoietin) 2000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	530.00
	73	780	pc	Epoetin Beta (recombinant erythropoietin) 5000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	1,272.18
	74	3,600	pc	Ertapenem sodium 1gm powder vial (IM/IV)	2,818.98
	75	1,920	pc	Esmolol Hydrochloride 10mg/mL, 10mL vial (IV)	686.34
	76	1,500	pc	Etoposide 20mg/mL, 5mL ampule/vial (IV)	345.00
	77	2,640	pc	Famotidine 20 mg powder/lyophilized powder for injection, ampule/vial (IV)	134.03
	78	39,756	pc	Fentanyl citrate 50mcg/mL, 2mL amp (IV) (With PDEA Permit)	374.44
	79	615	pc	Filgrastim 150 micrograms/0.6 mL, vial (IV, SC)	1,100.00
	80	7,332	pc	Fluconazole 2mg/mL, 100mL vial (IV infusion)	600.00

	81	269	pc	Flumazenil 100 micrograms/mL, 5 mL ampul (slow IV, IV infusion)	2,000.00
	82	180	pc	Fluphenazine (as decanoate) 25mg/mL, 1mL ampule (IM)	79.44
	83	720	pc	Fluorescein (as sodium salt) 10% (100mg/mL), 5 mL ampul (IV)	575.00
	84	10,500	pc	Fluorouracil 50 mg/mL, 10 mL ampul/vial (IV, IV infusion)	74.80
	85	180	pc	Fondaparinux sodium 2.5 mg/0.5 mL solution (IV, SC)	360.00
	86	51,240	pc	Furosemide 10 mg/mL, 2 mL ampul (IM, IV)	20.00
	87	180	pc	Ganciclovir sodium 500 mg vial (IV infusion)	2,299.90
	88	810	pc	Gemcitabine Hydrochloride 1gm vial (IV infusion)	2,987.00
	89	1,500	pc	Gemcitabine Hydrochloride 200mg vial (IV infusion)	722.00
	90	26,184	pc	Gentamicin sulfate 40mg/mL, 2mL ampule/vial (IM, IV)	14.88
	91	18,636	pc	Glucose (dextrose) 50%, 50mL vial (IV)	114.00
	92	7,440	pc	Glyceryl trinitrate (nitroglycerin) 1mg/mL, 10mL ampule (IV infusion)	436.80
	93	72	pc	Goserelin acetate 10.8mg depot solution pre-filled syringe (SC)	15,767.24
	94	72	pc	Goserelin acetate 3.6mg depot solution, pre-filled syringe (SC)	4,613.06
	95	1,200	pc	Haloperidol 5 mg/mL, 1 mL ampul (IM)	730.00
	96	5,040	pc	Heparin sodium unfractionated 1,000 iu/mL, 5mL vial (IV infusion, SC) (bovine origin)	135.00
	97	5,592	pc	Heparin sodium unfractionated 5000 IU/mL, 5 mL vial (IV infusion, SC) (bovine origin)	262.34
	98	60	pc	Human recombinant tissue type plasminogen activator (alteplase) 50 mg powder for I.V. infusion	30,536.02
	99	444	pc	Hydralazine Hydrochloride 20 mg/mL, 1 mL ampul (IM, IV)	232.00
	100	9,120	pc	Hydrocortisone sodium succinate 50mg/mL, 2mL vial or 100mg powder vial (IV)	164.45
	101	4,800	pc	Hydrocortisone sodium succinate 125 mg/mL, 2 mL vial (IV) or 250 mg powder vial (IV)	370.00
	102	8,292	pc	Hyoscine-n-butylbromide 20mg/mL, 1mL ampule (IM, IV, SC)	35.00
	103	60	pc	Idarubicin (as hydrochloride) powder, 5 mg vial (IV)	7,312.74

	104	2,500	pc	Ifosfamide powder, 2gms vial (IV infusion)	2,900.00
	105	2,500	pc	Ifosfamide powder, 1g vial (IV infusion)	1,500.00
	106	1,464	pc	Insulin, regular(recombinant DNA human) 100 IU/mL, 10mL vial (SC, IV/IM)	810.00
	107	720	pc	Insulin, Biphasic Isophane Human 70/30 (recombinant DNA) 70% isophane suspension + 30% soluble insulin in 100 IU/mL, 10 mL vial (SC)	595.00
	108	1,440	pc	Isophane Insulin Human (recombinant DNA) 100 IU/mL, 10 mL vial (SC)	425.00
	109	1,392	pc	Isosorbide dinitrate 1mg/ml, 10mL ampule (IV)	540.00
	110	5,800	pc	Iron sucrose 20mg/mL, 5mL ampule (IV, IV infusion)	200.00
	111	480	pc	Isoxsuprine hydrochloride 5 mg/mL, 2 mL ampul (IM, IV infusion)	260.00
	112	409	pc	Ketamine hydrochloride 50 mg/mL, 10 mL vial (IM, IV) (With PDEA Permit)	1,499.00
	113	53,100	pc	Ketorolac tromethamol 30 mg/mL, 1 mL ampul (IM, IV)	25.00
	114	5,064	pc	Levetiracetam 500 mg/5 mL (100 mg/mL) concentrate solution for IV infusion, 5 mL vial	1,908.00
	115	7,200	pc	Levofloxacin 5 mg/mL solution for IV infusion, 100mL vial	965.00
	116	51,200	pc	Lidocaine Hydrochloride 2%, 5mL ampule/vial (IM/IV)	46.00
	117	10,080	pc	Lidocaine Hydrochloride 2%, 50mL ampule/vial (IM, IV)	51.00
	118	2,400	pc	Lidocaine Hydrochloride 2%, 1.8 mL carpule (with epinephrine) (local infiltration)	27.00
	119	1,440	pc	Linezolid 2 mg/mL (600 mg/300 mL), solution for infusion (IV)	4,152.50
	120	9,456	pc	Magnesium sulfate heptahydrate 250mg/mL, 20mL vial (IV)	95.00
	121	5,640	pc	Mesna (sodium-2mercapto ethanesulphonate) 100mg/mL, 4mL ampule (IV)	161.70
	122	4,680	pc	Methotrexate 25 mg/mL, 2 mL ampul/vial (IM, IV, Intrathecal) (as base)	205.50
	123	630	pc	Methotrexate sodium 100mg/mL, 10mL vial (IM, IV, Intrathecal) (preservative free)	5,505.50
	124	339	pc	Methylergometrine (methylergonovine) (as hydrogen maleate or maleate) 200 micrograms/mL, 1 mL ampul (IM, IV)	64.00

	125	1,440	pc	Methylprednisolone 40 mg in single dose vial, solution for injection (IV, IM) (as sodium succinate)	716.85
	126	1,359	pc	Methylprednisolone lyophilized powder, 500 mg vial (IM, IV) (as sodium succinate)	2,403.50
	127	16,880	pc	Metoclopramide 5mg/mL, 2mL ampule (As Base and As Hydrochloride) (IM/IV)	20.00
	128	13,056	pc	Metronidazole 5 mg/mL, 100 mL vial (IV infusion)	57.00
	129	9,042	pc	Midazolam 1mg/mL, 5mL ampule or 5mg/mL, 1mL ampule (IM, IV) (With PDEA Permit)	155.00
	130	11,346	pc	Midazolam 5mg/mL, 3mL ampule (IM, IV) (With PDEA Permit)	589.98
	131	5,064	pc	Milrinone 10mg/ml, 10ml ampule (IV) (With Compassionate Special Permit)	890.40
	132	5,472	pc	Morphine Sulfate 10 mg/mL, 1 mL ampul (IM, IV, SC) or 16 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	70.00
	133	2,394	pc	Nalbuphine Hydrochloride 10 mg/mL, 1 mL ampul (IM, IV, SC) (With PDEA Permit)	102.78
	134	1,440	pc	Naloxone hydrochloride 400 micrograms/mL, 1 mL ampul (IM, IV, SC)	272.48
	135	18,830	pc	Neostigmine 500 mcg/mL solution for injection (IM/IV/SC), 1 mL ampule	126.50
	136	1,320	pc	Nicardipine Hydrochloride 1mg/mL, 2mL ampule (IV)	389.90
	137	48,000	pc	Norepinephrine bitartrate 1mg/mL, 2mL ampule (IV infusion)	210.00
	138	50,640	pc	Norepinephrine bitartrate 1mg/mL, 4mL ampule (IV infusion)	400.00
	139	1,000	pc	Norepinephrine bitartrate 2 mg /mL, 4 mL ampule (8 mg/4 mL) solution for injection	1,701.56
	140	3,840	pc	Octreotide acetate 100 micrograms/mL ampul (IV infusion)	650.00
	141	50,520	pc	Omeprazole powder, 40 mg vial + 10 mL solvent ampul/vial (IV)	335.00
	142	9,000	pc	Ondansetron 2mg/mL, 2mL ampule (IM, IV)	730.00
	143	26,220	pc	Ondansetron 2mg/mL, 4mL ampule (IM, IV)	450.00
	144	25,320	pc	Oxacillin sodium 500mg vial (IM, IV)	130.00
	145	6,000	pc	Oxaliplatin 50mg vial powder (IV Infusion)	1,493.00
	146	9,820	pc	Oxytocin (synthetic) 10 IU/mL, 1 mL ampul (IM, IV)	241.90

	147	2,500	pc	Paclitaxel 6mg/mL, 16.7mL vial or 17mL vial (IV, IV infusion) (with special IV line)	1,650.00
	148	1,500	pc	Paclitaxel 6mg/mL, 25mL vial (IV, IV infusion) (with special IV line)	5,500.00
	149	1,650	pc	Paclitaxel 6mg/mL, 43.4mL vial (IV, IV infusion) (with special IV line)	5,060.00
	150	150,550	pc	Paracetamol 150mg/mL, 2mL ampule solution for injection (IM, IV)	26.00
	151	7,812	pc	Paracetamol 10 mg/mL, 50 mL vial solution for infusion (IV)	217.80
	152	8,160	pc	Paracetamol 10 mg/mL, 100 mL vial solution for infusion (IV)	200.00
	153	2,400	pc	Penicillin G benzathine (benzathine benzylpenicillin) 1,200,000 units vial (MR) (IM)	190.00
	154	7,464	pc	Penicillin G crystalline (benzylpenicillin) sodium 1,000,000 units vial (IM, IV)	18.00
	155	2,664	pc	Penicillin G crystalline (benzylpenicillin) sodium 5,000,000 units vial (IM, IV)	21.00
	156	5,500	pc	Pethidine (meperidine) (as hydrochloride) 50 mg/mL, 2 mL ampul (IM, IV, SC) (With PDEA Permit)	253.78
	157	2,640	pc	Phenylephrine hydrochloride 10mg/1mL vial (With Compassionate Special Permit) (IV/IV Infusion)	554.40
	158	2,400	pc	Phenytoin sodium 50mg/mL, 2mL ampule (IV)	650.00
	159	9,528	pc	Phytomenadione (phytonadione, vitamin K1) 10mg/mL, 1mL ampul (IM, IV, SC) (as mixed micelle)	45.89
	160	13,420	pc	Polymyxin B sulfate 500,000 Units powder for solution for injection (Intrathecal/IM/IV), 5 mL vial	2,793.96
	161	11,196	pc	Potassium chloride 2meq/mL, 20mL vial (IV infusion)	57.00
	162	18,856	pc	Propofol 10mg/mL, 20mL ampule/vial (IV)	563.73
	163	1,335	pc	Protamine sulfate 10mg/mL, 5mL ampule (IV) (With Compassionate Special Permit)	678.00
	164	12,264	pc	Ranitidine hydrochloride 25 mg/mL, 2 mL ampul/vial (IM, IV, IV infusion)	23.78
	165	1,980	pc	Remifentanil 1mg lyophilized powder vial (IV Infusion) (With PDEA Permit)	1,648.90
	166	150	pc	Rituximab 10mg/mL, 50mL vial (IV)	47,673.39
	167	50	pc	Rituximab 10mg/mL, 10mL vial (IV)	9,783.74

	168	4,314	pc	Rocuronium bromide 10 mg/mL, 5 mL ampul/vial (IV)	218.18
	169	2,640	pc	Ropivacaine Hydrochloride 10mg/mL, 10mL ampule (IV)	400.00
	170	15,000	pc	Sodium Bicarbonate 1 mEq/mL, 20 mL ampul/vial (adult) (IV infusion)	179.88
	171	11,500	pc	Sodium bicarbonate 1mEq/mL, 50mL ampul/vial (adult) (IV infusion)	205.00
	172	7,728	pc	Sodium Chloride 2.5mEq/mL, 20mL vial	55.00
	173	195	pc	Somatostatin 3mg ampule/vial (IV, IV infusion)	4,630.90
	174	2,945	pc	Sugammadex 100 mg/mL solution for injection (IV), 2 mL vial	5,782.70
	175	2,883	pc	Suxamethonium (succinylcholine) chloride 20 mg/mL, 10 mL vial (IV)	300.00
	176	768	pc	Terbutaline sulfate 500mcg/mL, 1mL ampule (IM, IV, SC)	48.28
	177	25,260	pc	Tramadol Hydrochloride 50mg/mL, 1mL ampule (IM, IV, SC)	41.00
	178	13,320	pc	Tramadol Hydrochloride 50mg/mL, 2mL ampule (IM, IV, SC)	95.00
	179	40,260	pc	Tranexamic acid 100mg/mL, 5mL ampule (IM, IV)	130.00
	180	3,415	pc	Trastuzumab 150 mg lyophilized powder (IV infusion) vial	10,267.81
	181	650	pc	Trastuzumab 600 mg/5 mL (120 mg/mL) solution for injection (SC), 5 mL vial	25,535.70
	182	50	pc	Valproic Acid 500 mg/ 5mL IV infusion, 5 mL vial	3,541.00
	183	2,664	pc	Vasopressin 20 IU/mL (IM, IV)	1,490.00
	184	372	pc	Verapamil Hydrochloride 2.5 mg/mL, 2 mL ampul (IV)	127.94
	185	300	pc	Vinblastine sulfate 1 mg/mL, 10 mL vial (IV)	1,001.00
	186	1,300	pc	Vincristine sulfate 1 mg/mL, 1 mL vial (IV)	395.88
	187	1,420	pc	Vincristine sulfate 1 mg/mL, 2 mL vial (IV)	436.15
	188	300	pc	Vitamin B1 B6 B12 100 mg B1 + 100 mg B6 + 1 mg B12 per 3 mL ampul (IV)	35.00
	189	600	pc	Voriconazole 200mg lyophilized powder for solution for IV infusion, 30mLVial	5,167.80
	TOTAL APPROVED BUDGET FOR THE CONTRACT: PhP625,712,164.01				
	Terms and Conditions:				
	1. Indicate the **brand and packing of the item/s** offered.				

	2. The brand offered must be **<u>at least five (5) years</u> commercially available in the market from date of opening of bids.** Proof of this shall be the initial Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).
	3. **Submit the following documents, submission should be per product, with tab and per item number. <u>Two (2) copies for the Valid Certificate of Product Registration and Certificate of Analysis (COA).</u>**
	3.1 **Memorandum of Agreement (MOA) and Certificate of exclusive/authorized distributorship between the manufacturer and distributor.** Distributors/suppliers must have certification from their principals that they are the exclusive distributor of the drug products authorized to submit tender for the product on behalf of the principal and that all commitments made by them shall be honored by the principal in case of termination of distributorship agreement.
	3.2 **Valid Certificate of Product Registration (CPR)** issued by the Food and Drug Administration (FDA). • **The name of the respective distributor should appear in the submitted CPR of the drug**. <u>Note</u>: *CPRs that will expire within three (3) months from the date of opening of bids should present the Official Receipt of renewal of application with the Document Tracking log for the CPR from the FDA.*
	3.3 **Certificate of Analysis (COA)** for the products offered (batch to be delivered if awarded) duly issued by an FDA accredited laboratory (local) and should contain information indicated in monograph of the drug. Sample analyzed must not be expired during the time of bidding. The result of assay submitted must be in the specific brand and should be in the exact dosage formulation of the drug being bidded. In cases where local laboratories are unavailable to perform drug assays, assays done abroad is accepted. The local COA is preferred and given more weight in the evaluation and awarding process.
	3.4 **A notarized certificate** that it is the innovator drug (if applicable).
	3.5 **Certificate of Current Good Manufacturing Practice** (CGMP).
	3.6 **Valid License to Operate** (LTO).
	3.7 A notarized certificate that the offered brand has not been subject to product complaint/product recall for the past three (3) years.
	3.8 Certificate of Acceptance from at least three (3) major hospital issued within the year and should be supported with Sales Invoice (*for new item/brand offered only)*.
	3.9 A notarized certificate that there are sufficient stocks for the offered item/s for one (1) year.
	4. The offered drug must conform to the latest Philippine Food and Drug Administration (FDA) Administrative Order **governing the generic labeling and packaging requirements.**
	4.1 For all tablets and capsules
	4.1.1 **All tablets/capsules should be in foil or blister pack. A picture of the blister pack (front and back) should be submitted.**
	4.1.2 Each individual flap in the tablet or capsule blister pack should be labeled with the generic name and brand.
	4.1.3 Dosage form and strength of the Active Pharmaceutical Ingredients (API) should appear on each unit or every 2 units for products with multiple APIs.

	4.1.4 Name of drug, lot or batch number and expiry date must appear on every standard blister pack/foil strip and on the container or inner packing. However, if the product is not restricted for dispensing in quantities less than the standard blister pack or foil strip, the batch or lot number and expiry date should appear on each unit.
	4.1.5 Inner label must be the same as the outer label.
	4.1.6 A complete drug literature/product insert must accompany the product.
	5. The following must be complied with specific for **cytotoxic injectable drugs.**
	5.1 For cytotoxic injectable drugs, winning bidders are required to *provide Material Safety Data Sheet (MSDS) and to submit Drug Profile* to the Pharmacy Department per company under the first Purchase Order.
	5.2 Winning bidders for cytotoxic injectable drugs are required to **provide at least three (3) spill kits** per company under the first Purchase Order.
	6. The brand offered on all antibiotics must have stability that is equivalent to that of the innovator product or better.
	7. **New brands offered** shall be subject to further evaluation and shall require the following:
	7.1. Validation of the submitted Certificate of Acceptance from at least three (3) major hospitals
	7.2. Justification from end-user/s to validate the acceptance of the good/s offered (to be facilitated by PGH-PSD).
	8. **For the supply and delivery of awarded drugs and medicines.**
	8.1. Delivery of the goods is required as stated in the request of the end-user, commencing on the 3rd working day of notification through confirmed fax/email that the approved Call-off/ Notice to Supplier (NTS) is already available for pick up.
	8.2. Delivery schedule (whichever is applicable): 8.2.1. within seven (7) calendar days; 8.2.2. as may be called for; 8.2.3. staggered delivery within three (3) months * 50% of the total quantity within seven (7) calendar days and 25% each for the succeeding months *Note: The end-user has the right to adjust the quantity to be delivered depending on the actual need of the hospital*
	8.3. Deliveries shall have **at least two (2) years expiration date.**
	8.4. Delivery of goods **with product complaint shall be put on hold** until receipt of the final decision of the PGH management whether to proceed with the acceptance or to cancel/return the items
	8.5. Delivered **items found to be non-formulary at any given time shall be returned** to the company and a credit memo shall be issued.
	8.6. Stocks delivered are subject to random sampling for testing as to quality and conformity to label. Testing fee at supplier's expense.

	8.7. Stocks with lot #/batch different from the submitted Certificate of Analysis (COA) will be subjected to testing as to quality and conformity to label. Testing fee at supplier's expense.
	8.8.All items that had been pulled out for various reasons, a credit memo shall be issued by the Contractor within one (1) month, otherwise, a debit memo shall be processed by UP Manila - PGH and the amount will be deducted from any amount due to Supplier.
	8.9.It is understood that the Supplier is legally responsible to deliver all issued **CALL-OFF/s** (Purchase Order) and **failure to deliver the first Call-Off as scheduled shall mean automatic cancellation of the Call-Off and Notice to Execute Framework Agreement (NEFA).** Purchase from other source for whatever means shall be effected immediately to provide the requirements of the hospital. Penalty to the defaulting contractor shall be charged accordingly.
	9. **Failure to comply with the submission of the required documents shall be ground for post-disqualification in accordance with RA 9184.**
	10. Compliance with RA 9184 and other applicable laws.
20.2	1. Latest Income and Business Tax returns filed and paid through the BIR Electronic Filing and Payment System (eFPS) 2. License to Operate (LTO) if applicable.
21.2	Not applicable

Section IV. General Conditions of Contract

Notes on the General Conditions of Contract

The General Conditions of Contract (GCC) in this Section, read in conjunction with the Special Conditions of Contract in Section V and other documents listed therein, should be a complete document expressing all the rights and obligations of the parties.

Matters governing performance of the Supplier, payments under the contract, or matters affecting the risks, rights, and obligations of the parties under the contract are included in the GCC and Special Conditions of Contract.

Any complementary information, which may be needed, shall be introduced only through the Special Conditions of Contract.

1. Scope of Contract

This Contract shall include all such items, although not specifically mentioned, that can be reasonably inferred as being required for its completion as if such items were expressly mentioned herein. All the provisions of RA No. 9184 and its 2016 revised IRR, including the Generic Procurement Manual, and associated issuances, constitute the primary source for the terms and conditions of the Contract, and thus, applicable in contract implementation. Herein clauses shall serve as the secondary source for the terms and conditions of the Contract.

This is without prejudice to Sections 74.1 and 74.2 of the 2016 revised IRR of RA No. 9184 allowing the GPPB to amend the IRR, which shall be applied to all procurement activities, the advertisement, posting, or invitation of which were issued after the effectivity of the said amendment.

Additional requirements for the completion of this Contract shall be provided in the **Special Conditions of Contract** (**SCC).**

2. Advance Payment and Terms of Payment

2.1. Advance payment of the contract amount is provided under Annex "D" of the revised 2016 IRR of RA No. 9184.

2.2. The Procuring Entity is allowed to determine the terms of payment on the partial or staggered delivery of the Goods procured, provided such partial payment shall correspond to the value of the goods delivered and accepted in accordance with prevailing accounting and auditing rules and regulations. The terms of payment are indicated in the **SCC**.

2.3. For a single-year Framework Agreement, prices charged by the Supplier for Goods delivered and/or services performed under a Call-Off shall not vary from the prices quoted by the Supplier in its bid.

2.4. For multi-year Framework Agreement, prices charged by the Supplier for Goods delivered and/or services performed under a Call-Off shall not vary from the prices quoted by the Supplier during conduct of Mini-Competition.

3. Performance Security

Within ten (10) calendar days from receipt of the Notice of Award by the Bidder from the Procuring Entity but in no case later than prior to the signing of the Contract by both parties, the successful Bidder shall furnish the performance security in any of the forms prescribed in Section 39 of the 2016 revised IRR of RA No. 9184. *In the case of* Framework Agreement, the Bidder may opt to furnish the performance security or a Performance Securing Declaration as defined under the Guidelines on the Use of Framework Agreement.

4. Inspection and Tests

The Procuring Entity or its representative shall have the right to inspect and/or to test the Goods to confirm their conformity to the Project or Framework Agreement specifications at no extra cost to the Procuring Entity in accordance with the Generic Procurement Manual. In addition to tests in the **SCC**, **Section IV (Technical Specifications)** shall specify what inspections and/or tests the Procuring Entity requires, and where they are to be conducted. The Procuring Entity shall notify the Supplier in writing, in a timely manner, of the identity of any representatives retained for these purposes.

All reasonable facilities and assistance for the inspection and testing of Goods, including access to drawings and production data, shall be provided by the Supplier to the authorized inspectors at no charge to the Procuring Entity.

5. Warranty

6.1. In order to assure that manufacturing defects shall be corrected by the Supplier, a warranty shall be required from the Supplier as provided under Section 62.1 of the 2016 revised IRR of RA No. 9184.

6.2. The Procuring Entity shall promptly notify the Supplier in writing of any claims arising under this warranty. Upon receipt of such notice, the Supplier shall, repair or replace the defective Goods or parts thereof without cost to the Procuring Entity, pursuant to the Generic Procurement Manual.

6. Liability of the Supplier

The Supplier's liability under this Contract shall be as provided by the laws of the Republic of the Philippines.

If the Supplier is a joint venture, all partners to the joint venture shall be jointly and severally liable to the Procuring Entity.

Section V. Special Conditions of Contract

Notes on the Special Conditions of Contract

Similar to the BDS, the clauses in this Section are intended to assist the Procuring Entity in providing contract-specific information in relation to corresponding clauses in the GCC found in Section IV.

The Special Conditions of Contract (SCC) complement the GCC, specifying contractual requirements linked to the special circumstances of the Procuring Entity, the Procuring Entity's country, the sector, and the Goods purchased. In preparing this Section, the following aspects should be checked:

a. Information that complements provisions of the GCC must be incorporated.

b. Amendments and/or supplements to provisions of the GCC as necessitated by the circumstances of the specific purchase, must also be incorporated.

However, no special condition which defeats or negates the general intent and purpose of the provisions of the GCC should be incorporated herein.

Special Conditions of Contract

GCC Clause	
1	**Delivery and Documents –** For purposes of the Contract, "EXW," "FOB," "FCA," "CIF," "CIP," "DDP" and other trade terms used to describe the obligations of the parties shall have the meanings assigned to them by the current edition of INCOTERMS published by the International Chamber of Commerce, Paris. The Delivery terms of this Contract shall be as follows: *[For Goods supplied from abroad, state:]* "The delivery terms applicable to the Contract are DDP delivered [*indicate place of destination*]. In accordance with INCOTERMS." "The delivery terms applicable to this Contract are delivered [*indicate place of destination*]. Risk and title will pass from the Supplier to the ***University of the Philippines Manila – Philippine General Hospital*** upon receipt and final acceptance of the Goods at their final destination." Delivery of the Goods shall be made by the Supplier in accordance with the terms specified in Section VI (Schedule of Requirements). For purposes of this Clause the Procuring Entity's Representative at the Project Site is the assigned staff. **Incidental Services –** The Supplier is required to provide all of the following services, including additional services, if any, specified in Section VI. Schedule of Requirements: a. performance or supervision of on-site assembly and/or start-up of the supplied Goods; b. furnishing of tools required for assembly and/or maintenance of the supplied Goods; c. furnishing of a detailed operations and maintenance manual for each appropriate unit of the supplied Goods; d. training of the Procuring Entity's personnel, at the Supplier's plant and/or on-site, in assembly, start-up, operation, maintenance, and/or repair of the supplied Goods. The Contract price for the Goods shall include the prices charged by the Supplier for incidental services and shall not exceed the prevailing rates charged to other parties by the Supplier for similar services.
	Spare Parts – The Supplier is required to provide all of the following materials, notifications, and information pertaining to spare parts manufactured or distributed by the Supplier:

	a. such spare parts as the *University of the Philippines Manila – Philippine General Hospital* may elect to purchase from the Supplier, provided that this election shall not relieve the Supplier of any warranty obligations under this Contract; and b. in the event of termination of production of the spare parts: i. advance notification to the Procuring Entity of the pending termination, in sufficient time to permit the Procuring Entity to procure needed requirements; and ii. following such termination, furnishing at no cost to the Procuring Entity, the blueprints, drawings, and specifications of the spare parts, if requested. The spare parts and other components required are listed in **Section VI (Schedule of Requirements)** and the cost thereof are included in the contract price. The Supplier shall carry sufficient inventories to assure ex-stock supply of consumable spare parts or components for the Goods for a period of **[S*ee attached Terms and Conditions*]**. Spare parts or components shall be supplied as promptly as possible, but in any case, within **[*See attached Terms and Conditions*]** months of placing the order.
	Packaging – The Supplier shall provide such packaging of the Goods as is required to prevent their damage or deterioration during transit to their final destination, as indicated in this Contract. The packaging shall be sufficient to withstand, without limitation, rough handling during transit and exposure to extreme temperatures, salt and precipitation during transit, and open storage. Packaging case size and weights shall take into consideration, where appropriate, the remoteness of the Goods' final destination and the absence of heavy handling facilities at all points in transit. The packaging, marking, and documentation within and outside the packages shall comply strictly with such special requirements as shall be expressly provided for in the Contract, including additional requirements, if any, specified below, and in any subsequent instructions ordered by the Procuring Entity.
	The outer packaging must be clearly marked on at least four (4) sides as follows: Name of the Procuring Entity Name of the Supplier Contract Description Final Destination Gross weight Any special lifting instructions Any special handling instructions Any relevant HAZCHEM classifications

	A packaging list identifying the contents and quantities of the package is to be placed on an accessible point of the outer packaging if practical. If not practical the packaging list is to be placed inside the outer packaging but outside the secondary packaging. **Transportation –** Where the Supplier is required under Contract to deliver the Goods CIF, CIP, or DDP, transport of the Goods to the port of destination or such other named place of destination in the Philippines, as shall be specified in this Contract, shall be arranged and paid for by the Supplier, and the cost thereof shall be included in the Contract Price. Where the Supplier is required under this Contract to transport the Goods to a specified place of destination within the Philippines, defined as the Project Site, transport to such place of destination in the Philippines, including insurance and storage, as shall be specified in this Contract, shall be arranged by the Supplier, and related costs shall be included in the contract price.
	Where the Supplier is required under Contract to deliver the Goods CIF, CIP or DDP, Goods are to be transported on carriers of Philippine registry. In the event that no carrier of Philippine registry is available, Goods may be shipped by a carrier which is not of Philippine registry provided that the Supplier obtains and presents to the *University of the Philippines Manila – Philippine General Hospital* certification to this effect from the nearest Philippine consulate to the port of dispatch. In the event that carriers of Philippine registry are available but their schedule delays the Supplier in its performance of this Contract the period from when the Goods were first ready for shipment and the actual date of shipment the period of delay will be considered force majeure.
	The *University of the Philippines Manila – Philippine General Hospital* accepts no liability for the damage of Goods during transit other than those prescribed by INCOTERMS for DDP deliveries. In the case of Goods supplied from within the Philippines or supplied by domestic Suppliers risk and title will not be deemed to have passed to the *University of the Philippines Manila – Philippine General Hospital* until their receipt and final acceptance at the final destination.
	Intellectual Property Rights – The Supplier shall indemnify the *University of the Philippines Manila – Philippine General Hospital* against all third-party claims of infringement of patent, trademark, or industrial design rights arising from use of the Goods or any part thereof.
4	The inspections and tests that will be conducted are: *[Indicate the applicable inspections and tests]*

Section VI. Framework Agreement List

Limited to repeatedly required goods and services that are identified to be necessary and desirable, but, by its nature, use or characteristic, the quantity and/ or exact time of need cannot be accurately pre-determined and are not advisable to be carried in stock.

Prepared by the End-User, attached to the APP and submitted to the BAC for the approval of the HOPE.

FRAMEWORK AGREEMENT LIST (AGENCY)				
Item / Service Type and nature of each item/service		***Unit Cost per item or service***	***Maximum Quantity***	***Total Cost per Item***
1	Acetylcysteine 200mg/mL, 25mL vial/bottle (IV infusion)	1,813.00	720	1,305,360.00
2	Aciclovir 25mg/mL, 10mL vial (IV infusion)	977.43	4,800	4,691,664.00
3	Albumin Human 20%, 50mL bottle (IV, IV infusion)	2,100.00	3,144	6,602,400.00
4	Adenosine 3 mg/mL, 2 mL vial (IV)	1,960.00	1,114	2,182,460.00
5	Amikacin sulfate 125mg/mL , 2mL ampule/vial (IM, IV)	386.00	12,000	4,632,000.00
6	Amikacin sulfate 250mg/mL , 2mL ampule/vial (IM, IV)	97.44	14,928	1,454,584.32
7	Aminophylline (theophylline ethylenediamine) 25 mg/mL, 10 mL ampul (IV)	45.00	1,200	54,000.00
8	Amiodarone hydrochloride 50 mg/mL, 3 mL ampul (IV)	448.00	5,750	2,576,000.00
9	Amphotericin B non lipid complex 50mg lyophilized powder, vial (IV infusion)	2,448.00	720	1,762,560.00
10	Amphotericin B Lipid Complex (as cholesteryl complex, colloidal dispersion) 50 mg vial (IV infusion)	13,499.00	1,440	19,438,560.00
11	Ampicillin + Sulbactam 1000 mg ampicillin + 500 mg sulbactam (IM, IV) (as sodium salt) per vial	310.00	24,000	7,440,000.00
12	Ampicillin + Sulbactam 500 mg ampicillin + 250 mg sulbactam (IM, IV) (as sodium salt) per vial	210.00	25,320	5,317,200.00
13	Ampicillin sodium 250mg vial (IM, IV)	37.85	12,000	454,200.00
14	Ampicillin sodium 500mg vial (IM, IV)	54.00	13,320	719,280.00
15	Atracurium besilate 10mg/mL, 2.5mL ampule (IV)	230.00	16,380	3,767,400.00
16	Atropine sulfate 1mg/mL, 1 mL ampul (IM, IV, SC)	18.69	20,170	376,977.30
17	Azithromycin 500 mg powder, vial (IV infusion) (as base*/as dihydrate)	540.00	2,400	1,296,000.00

18	Aztreonam 1g powder for injection (IV, IV Infusion)	1,142.35	2,400	2,741,640.00
19	Basiliximab 20 mg vial (IV infusion)	60,445.83	13	785,795.79
20	Beractant 25 mg/ml suspension, 8mL Intratracheal administration vial	17,354.18	240	4,165,003.20
21	Beractant 25 mg/mL suspension, 4 mL Intratracheal administration vial	11,070.25	240	2,656,860.00
22	Bleomycin sulfate powder, 15 IU ampul/vial (IM,IV)	2,750.00	360	990,000.00
23	Bupivacaine Hydrochloride 0.5% 4 mL ampul (spinal) with 8% dextrose	457.00	8,280	3,783,960.00
24	Bupivacaine Hydrochloride 0.5%, 10mL ampul/vial (local infiltration)	341.78	18,000	6,152,040.00
25	Butorphanol tartrate 2 mg/mL, 1 mL ampul/vial (IM, IV)	508.93	2,655	1,351,209.15
26	Calcium folinate (leucovorin Ca) 10mg/mL, 5mL ampule/vial (IM, IV)	180.00	6,940	1,249,200.00
27	Calcium Gluconate 10%, 10 mL ampul/vial (IV)	164.00	25,470	4,177,080.00
28	Carbetocin 100 mcg/mL, 1 mL ampule/vial, solution for Injection (IV)	1,200.00	6,120	7,344,000.00
29	Carboprost 250 mcg/mL solution for injection, 1 mL ampule/vial	500.00	312	156,000.00
30	Carboplatin 10mg/mL, 15mL vial (IV)	890.00	1,575	1,401,750.00
31	Carboplatin 10mg/mL, 45mL vial (IV)	3,900.00	2,450	9,555,000.00
32	Cefazolin sodium 1gm vial (IM, IV)	215.00	19,680	4,231,200.00
33	Cefepime Hydrochloride 1gm vial (IM, IV)	312.50	4,800	1,500,000.00
34	Cefepime Hydrochloride 2gms vial (IM, IV)	441.10	2,400	1,058,640.00
35	Cefotaxime sodium 500 mg vial + 2 mL diluent (IM, IV)	740.50	2,400	1,777,200.00
36	Ceftazidime pentahydrate 1gm vial (IM, IV)	210.00	17,748	3,727,080.00
37	Ceftriaxone disodium/sodium 1gm vial + 10mL diluent (IV)	368.00	25,320	9,317,760.00
38	Cefuroxime sodium 750mg vial (IM, IV)	90.00	19,680	1,771,200.00
39	Ciprofloxacin lactate 2mg/mL, 100mL vial (IV infusion)	241.08	7,200	1,735,776.00
40	Cisplatin 1mg/mL, 10mL vial (IV)	187.00	325	60,775.00
41	Cisplatin 1mg/mL, 50mL vial (IV)	450.00	1,500	675,000.00
42	Clindamycin phosphate 150mg/mL, 2mL ampule/vial (IM, IV)	198.00	25,320	5,013,360.00
43	Clindamycin phosphate 150mg/mL, 4mL ampule (IM, IV)	370.00	24,000	8,880,000.00

44	Colistin 2,000,000 IU lyophilized powder for injection (IV infusion)	2,232.14	1,090	2,433,032.60
45	Cyclophosphamide 500mg vial powder (IV)	220.00	2,715	597,300.00
46	Cyclophosphamide 1gm vial powder (IV)	350.00	2,715	950,250.00
47	Cytarabine 100 mg/mL solution for injection, 1 mL	130.00	3,015	391,950.00
48	Cytarabine 100 mg/mL solution for injection, 5 mL	376.00	2,115	795,240.00
49	Cytarabine 100 mg/mL solution for injection, 10 mL	1,607.14	2,115	3,399,101.10
50	Dacarbazine powder, 200mg vial (IV, IV infusion)	714.30	600	428,580.00
51	Dactinomycin powder, 500 micrograms vial (IV)	440.00	440	193,600.00
52	Dantrolene Sodium 20 mg (with mannitol 3g)/vial (for reconstitution with 60 mL sterile water for injection) (IV) (With Compassionate Special Permit)	16,170.00	396	6,403,320.00
53	Deferoxamine mesilate powder, 500 mg vial (IM, IV infusion, SC)	183.32	2,460	450,967.20
54	Dexamethasone sodium phoshate 4 mg/mL, 2 mL ampul/vial (IM, IV)	69.00	56,920	3,927,480.00
55	Dexamethasone sodium phoshate 5mg/mL, 1mL ampule (IM, IV)	67.23	53,400	3,590,082.00
56	Diazepam 5 mg/mL, 2 mL ampul (IM, IV) (With PDEA Permit)	138.22	990	136,837.80
57	Digoxin 250 micrograms/mL, 2 mL ampul (IM, IV)	310.00	984	305,040.00
58	Diphenhydramine Hydrochloride 50 mg/mL, 1 mL ampul (IM, IV)	98.00	20,770	2,035,460.00
59	Dobutamine Hydrochloride 50mg/mL, 5ml ampule (IV infusion)	490.00	3,726	1,825,740.00
60	Docetaxel anhydrous 20 mg/0.5 mL, 0.5 mL vial (IV infusion)	1,105.00	1,500	1,657,500.00
61	Docetaxel anhydrous 40 mg/mL, 2 mL vial (IV infusion)	3,220.00	750	2,415,000.00
62	Dopamine Hydrochloride 40mg/mL 5mL vial/ampule (IV)	234.50	3,720	872,340.00
63	Doxorubicin Hydrochloride powder, 50mg vial or 2mg/mL, 25mL vial (IV)	500.20	3,750	1,875,750.00
64	Enoxaparin sodium 100mg/mL, 0.4mL pre-filled syringe (SC)	794.00	24,300	19,294,200.00
65	Enoxaparin sodium 100mg/mL, 0.6mL pre-filled syringe (SC)	778.00	15,000	11,670,000.00

66	Ephedrine sulfate 50 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	86.50	3,300	285,450.00
67	Epinephrine Hydrochloride 1mg/mL, 1mL ampule (IV, IM, SC)	80.00	64,100	5,128,000.00
68	Epirubicin (as hydrochloride) powder, 50mg vial (IV)	2,943.33	75	220,749.75
69	Epoetin alfa (recombinant human erythropoetin) 10,000 IU/mL, pre-filled syringe (IV, SC)	1,458.00	384	559,872.00
70	Epoetin alfa (recombinant human erythropoetin) 4000 IU/0.4 mL, pre-filled syringe (IV, SC)	950.00	3,000	2,850,000.00
71	Epoetin alfa (recombinant human erythropoietin) 2000 IU/0.5 mL, pre-filled syringe (IV, SC)	542.86	480	260,572.80
72	Epoetin Beta (recombinant erythropoietin) 2000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	530.00	480	254,400.00
73	Epoetin Beta (recombinant erythropoietin) 5000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	1,272.18	780	992,300.40
74	Ertapenem sodium 1gm powder vial (IM/IV)	2,818.98	3,600	10,148,328.00
75	Esmolol Hydrochloride 10mg/mL, 10mL vial (IV)	686.34	1,920	1,317,772.80
76	Etoposide 20mg/mL, 5mL ampule/vial (IV)	345.00	1,500	517,500.00
77	Famotidine 20 mg powder/lyophilized powder for injection, ampule/vial (IV)	134.03	2,640	353,839.20
78	Fentanyl citrate 50mcg/mL, 2mL amp (IV) (With PDEA Permit)	374.44	39,756	14,886,236.64
79	Filgrastim 150 micrograms/0.6 mL, vial (IV, SC)	1,100.00	615	676,500.00
80	Fluconazole 2mg/mL, 100mL vial (IV infusion)	600.00	7,332	4,399,200.00
81	Flumazenil 100 micrograms/mL, 5 mL ampul (slow IV, IV infusion)	2,000.00	269	538,000.00
82	Fluphenazine (as decanoate) 25mg/mL, 1mL ampule (IM)	79.44	180	14,299.20
83	Fluorescein (as sodium salt) 10% (100mg/mL), 5 mL ampul (IV)	575.00	720	414,000.00
84	Fluorouracil 50 mg/mL, 10 mL ampul/vial (IV, IV infusion)	74.80	10,500	785,400.00
85	Fondaparinux sodium 2.5 mg/0.5 mL solution (IV, SC)	360.00	180	64,800.00
86	Furosemide 10 mg/mL, 2 mL ampul (IM, IV)	20.00	51,240	1,024,800.00
87	Ganciclovir sodium 500 mg vial (IV infusion)	2,299.90	180	413,982.00
88	Gemcitabine Hydrochloride 1gm vial (IV infusion)	2,987.00	810	2,419,470.00
89	Gemcitabine Hydrochloride 200mg vial (IV infusion)	722.00	1,500	1,083,000.00

90	Gentamicin sulfate 40mg/mL, 2mL ampule/vial (IM, IV)	14.88	26,184	389,617.92
91	Glucose (dextrose) 50%, 50mL vial (IV)	114.00	18,636	2,124,504.00
92	Glyceryl trinitrate (nitroglycerin) 1mg/mL, 10mL ampule (IV infusion)	436.80	7,440	3,249,792.00
93	Goserelin acetate 10.8mg depot solution pre-filled syringe (SC)	15,767.24	72	1,135,241.28
94	Goserelin acetate 3.6mg depot solution, pre-filled syringe (SC)	4,613.06	72	332,140.32
95	Haloperidol 5 mg/mL, 1 mL ampul (IM)	730.00	1,200	876,000.00
96	Heparin sodium unfractionated 1,000 iu/mL, 5mL vial (IV infusion, SC) (bovine origin)	135.00	5,040	680,400.00
97	Heparin sodium unfractionated 5000 IU/mL, 5 mL vial (IV infusion, SC) (bovine origin)	262.34	5,592	1,467,005.28
98	Human recombinant tissue type plasminogen activator (alteplase) 50 mg powder for I.V. infusion	30,536.02	60	1,832,161.20
99	Hydralazine Hydrochloride 20 mg/mL, 1 mL ampul (IM, IV)	232.00	444	103,008.00
100	Hydrocortisone sodium succinate 50mg/mL, 2mL vial or 100mg powder vial (IV)	164.45	9,120	1,499,784.00
101	Hydrocortisone sodium succinate 125 mg/mL, 2 mL vial (IV) or 250 mg powder vial (IV)	370.00	4,800	1,776,000.00
102	Hyoscine-n-butylbromide 20mg/mL, 1mL ampule (IM, IV, SC)	35.00	8,292	290,220.00
103	Idarubicin (as hydrochloride) powder, 5 mg vial (IV)	7,312.74	60	438,764.40
104	Ifosfamide powder, 2gms vial (IV infusion)	2,900.00	2,500	7,250,000.00
105	Ifosfamide powder, 1g vial (IV infusion)	1,500.00	2,500	3,750,000.00
106	Insulin, regular(recombinant DNA human) 100 IU/mL, 10mL vial (SC, IV/IM)	810.00	1,464	1,185,840.00
107	Insulin, Biphasic Isophane Human 70/30 (recombinant DNA) 70% isophane suspension + 30% soluble insulin in 100 IU/mL, 10 mL vial (SC)	595.00	720	428,400.00
108	Isophane Insulin Human (recombinant DNA) 100 IU/mL, 10 mL vial (SC)	425.00	1,440	612,000.00
109	Isosorbide dinitrate 1mg/ml, 10mL ampule (IV)	540.00	1,392	751,680.00
110	Iron sucrose 20mg/mL, 5mL ampule (IV, IV infusion)	200.00	5,800	1,160,000.00
111	Isoxsuprine hydrochloride 5 mg/mL, 2 mL ampul (IM, IV infusion)	260.00	480	124,800.00

112	Ketamine hydrochloride 50 mg/mL, 10 mL vial (IM, IV) (With PDEA Permit)	1,499.00	409	613,091.00
113	Ketorolac tromethamol 30 mg/mL, 1 mL ampul (IM, IV)	25.00	53,100	1,327,500.00
114	Levetiracetam 500 mg/5 mL (100 mg/mL) concentrate solution for IV infusion, 5 mL vial	1,908.00	5,064	9,662,112.00
115	Levofloxacin 5 mg/mL solution for IV infusion, 100mL vial	965.00	7,200	6,948,000.00
116	Lidocaine Hydrochloride 2%, 5mL ampule/vial (IM/IV)	46.00	51,200	2,355,200.00
117	Lidocaine Hydrochloride 2%, 50mL ampule/vial (IM, IV)	51.00	10,080	514,080.00
118	Lidocaine Hydrochloride 2%, 1.8 mL carpule (with epinephrine) (local infiltration)	27.00	2,400	64,800.00
119	Linezolid 2 mg/mL (600 mg/300 mL), solution for infusion (IV)	4,152.50	1,440	5,979,600.00
120	Magnesium sulfate heptahydrate 250mg/mL, 20mL vial (IV)	95.00	9,456	898,320.00
121	Mesna (sodium-2mercapto ethanesulphonate) 100mg/mL, 4mL ampule (IV)	161.70	5,640	911,988.00
122	Methotrexate 25 mg/mL, 2 mL ampul/vial (IM, IV, Intrathecal) (as base)	205.50	4,680	961,740.00
123	Methotrexate sodium 100mg/mL, 10mL vial (IM, IV, Intrathecal) (preservative free)	5,505.50	630	3,468,465.00
124	Methylergometrine (methylergonovine) (as hydrogen maleate or maleate) 200 micrograms/mL, 1 mL ampul (IM, IV)	64.00	339	21,664.00
125	Methylprednisolone 40 mg in single dose vial, solution for injection (IV, IM) (as sodium succinate)	716.85	1,440	1,032,264.00
126	Methylprednisolone lyophilized powder, 500 mg vial (IM, IV) (as sodium succinate)	2,403.50	1,359	3,265,154.75
127	Metoclopramide 5mg/mL, 2mL ampule (As Base and As Hydrochloride) (IM/IV)	20.00	16,880	337,600.00
128	Metronidazole 5 mg/mL, 100 mL vial (IV infusion)	57.00	13,056	744,192.00
129	Midazolam 1mg/mL, 5mL ampule or 5mg/mL, 1mL ampule (IM, IV) (With PDEA Permit)	155.00	9,042	1,401,510.00
130	Midazolam 5mg/mL, 3mL ampule (IM, IV) (With PDEA Permit)	589.98	11,346	6,693,913.08
131	Milrinone 10mg/ml, 10ml ampule (IV) (With Compassionate Special Permit)	890.40	5,064	4,508,985.60
132	Morphine Sulfate 10 mg/mL, 1 mL ampul (IM, IV, SC) or 16 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	70.00	5,472	383,040.00

133	Nalbuphine Hydrochloride 10 mg/mL, 1 mL ampul (IM, IV, SC) (With PDEA Permit)	102.78	2,394	246,055.32
134	Naloxone hydrochloride 400 micrograms/mL, 1 mL ampul (IM, IV, SC)	272.48	1,440	392,371.20
135	Neostigmine 500 mcg/mL solution for injection (IM/IV/SC), 1 mL ampule	126.50	18,830	2,381,995.00
136	Nicardipine Hydrochloride 1mg/mL, 2mL ampule (IV)	389.90	1,320	514,668.00
137	Norepinephrine bitartrate 1mg/mL, 2mL ampule (IV infusion)	210.00	48,000	10,080,000.00
138	Norepinephrine bitartrate 1mg/mL, 4mL ampule (IV infusion)	400.00	50,640	20,256,000.00
139	Norepinephrine bitartrate 2 mg /mL, 4 mL ampule (8 mg/4 mL) solution for injection	1,701.56	1,000	1,701,560.00
140	Octreotide acetate 100 micrograms/mL ampul (IV infusion)	650.00	3,840	2,496,000.00
141	Omeprazole powder, 40 mg vial + 10 mL solvent ampul/vial (IV)	335.00	50,520	16,924,200.00
142	Ondansetron 2mg/mL, 2mL ampule (IM, IV)	730.00	9,000	6,570,000.00
143	Ondansetron 2mg/mL, 4mL ampule (IM, IV)	450.00	26,220	11,799,000.00
144	Oxacillin sodium 500mg vial (IM, IV)	130.00	25,320	3,291,600.00
145	Oxaliplatin 50mg vial powder (IV Infusion)	1,493.00	6,000	8,958,000.00
146	Oxytocin (synthetic) 10 IU/mL, 1 mL ampul (IM, IV)	241.90	9,820	2,375,458.00
147	Paclitaxel 6mg/mL, 16.7mL vial or 17mL vial (IV, IV infusion) (with special IV line)	1,650.00	2,500	4,125,000.00
148	Paclitaxel 6mg/mL, 25mL vial (IV, IV infusion) (with special IV line)	5,500.00	1,500	8,250,000.00
149	Paclitaxel 6mg/mL, 43.4mL vial (IV, IV infusion) (with special IV line)	5,060.00	1,650	8,349,000.00
150	Paracetamol 150mg/mL, 2mL ampule solution for injection (IM, IV)	26.00	150,550	3,914,300.00
151	Paracetamol 10 mg/mL, 50 mL vial solution for infusion (IV)	217.80	7,812	1,701,453.60
152	Paracetamol 10 mg/mL, 100 mL vial solution for infusion (IV)	200.00	8,160	1,632,000.00
153	Penicillin G benzathine (benzathine benzylpenicillin) 1,200,000 units vial (MR) (IM)	190.00	2,400	456,000.00
154	Penicillin G crystalline (benzylpenicillin) sodium 1,000,000 units vial (IM, IV)	18.00	7,464	134,352.00

155	Penicillin G crystalline (benzylpenicillin) sodium 5,000,000 units vial (IM, IV)	21.00	2,664	55,944.00
156	Pethidine (meperidine) (as hydrochloride) 50 mg/mL, 2 mL ampul (IM, IV, SC) (With PDEA Permit)	253.78	5,500	1,395,790.00
157	Phenylephrine hydrochloride 10mg/1mL vial (With Compassionate Special Permit) (IV/IV Infusion)	554.40	2,640	1,463,616.00
158	Phenytoin sodium 50mg/mL, 2mL ampule (IV)	650.00	2,400	1,560,000.00
159	Phytomenadione (phytonadione, vitamin K1) 10mg/mL, 1mL ampul (IM, IV, SC) (as mixed micelle)	45.89	9,528	437,239.92
160	Polymyxin B sulfate 500,000 Units powder for solution for injection (Intrathecal/IM/IV), 5 mL vial	2,793.96	13,420	37,494,943.20
161	Potassium chloride 2meq/mL, 20mL vial (IV infusion)	57.00	11,196	638,172.00
162	Propofol 10mg/mL, 20mL ampule/vial (IV)	563.73	18,856	10,629,692.88
163	Protamine sulfate 10mg/mL, 5mL ampule (IV) (With Compassionate Special Permit)	678.00	1,335	905,130.00
164	Ranitidine hydrochloride 25 mg/mL, 2 mL ampul/vial (IM, IV, IV infusion)	23.78	12,264	291,637.92
165	Remifentanil 1mg lyophilized powder vial (IV Infusion) (With PDEA Permit)	1,648.90	1,980	3,264,822.00
166	Rituximab 10mg/mL, 50mL vial (IV)	47,673.39	150	7,151,008.50
167	Rituximab 10mg/mL, 10mL vial (IV)	9,783.74	50	489,187.00
168	Rocuronium bromide 10 mg/mL, 5 mL ampul/vial (IV)	218.18	4,314	941,228.52
169	Ropivacaine Hydrochloride 10mg/mL, 10mL ampule (IV)	400.00	2,640	1,056,000.00
170	Sodium Bicarbonate 1 mEq/mL, 20 mL ampul/vial (adult) (IV infusion)	179.88	15,000	2,698,200.00
171	Sodium bicarbonate 1mEq/mL, 50mL ampul/vial (adult) (IV infusion)	205.00	11,500	2,357,500.00
172	Sodium Chloride 2.5mEq/mL, 20mL vial	55.00	7,728	425,040.00
173	Somatostatin 3mg ampule/vial (IV, IV infusion)	4,630.90	195	903,025.50
174	Sugammadex 100 mg/mL solution for injection (IV), 2 mL vial	5,782.70	2,945	17,030,051.50
175	Suxamethonium (succinylcholine) chloride 20 mg/mL, 10 mL vial (IV)	300.00	2,883	864,750.00
176	Terbutaline sulfate 500mcg/mL, 1mL ampule (IM, IV, SC)	48.28	768	37,079.04
177	Tramadol Hydrochloride 50mg/mL, 1mL ampule (IM, IV, SC)	41.00	25,260	1,035,660.00

178	Tramadol Hydrochloride 50mg/mL, 2mL ampule (IM, IV, SC)	95.00	13,320	1,265,400.00
179	Tranexamic acid 100mg/mL, 5mL ampule (IM, IV)	130.00	40,260	5,233,800.00
180	Trastuzumab 150 mg lyophilized powder (IV infusion) vial	10,267.81	3,415	35,064,571.15
181	Trastuzumab 600 mg/5 mL (120 mg/mL) solution for injection (SC), 5 mL vial	25,535.70	650	16,598,205.00
182	Valproic Acid 500 mg/ 5mL IV infusion, 5 mL vial	3,541.00	50	177,050.00
183	Vasopressin 20 IU/mL (IM, IV)	1,490.00	2,664	3,969,360.00
184	Verapamil Hydrochloride 2.5 mg/mL, 2 mL ampul (IV)	127.94	372	47,593.68
185	Vinblastine sulfate 1 mg/mL, 10 mL vial (IV)	1,001.00	300	300,300.00
186	Vincristine sulfate 1 mg/mL, 1 mL vial (IV)	395.88	1,300	514,644.00
187	Vincristine sulfate 1 mg/mL, 2 mL vial (IV)	436.15	1,420	619,333.00
188	Vitamin B1 B6 B12 100 mg B1 + 100 mg B6 + 1 mg B12 per 3 mL ampul (IV)	35.00	300	10,500.00
189	Voriconazole 200mg lyophilized powder for solution for IV infusion, 30mLVial	5,167.80	600	3,100,680.00
TOTAL ***(Approved Budget for the Contract)***				**PhP625,712,164.01**
Expected delivery timeframe after receipt of a Call-Off.				*Within **seven (7) calendar days** upon issuance of Call-off .*
Remarks				*Please refer to the Terms and Conditions*
Sgd. ***MARIA BERNADETTE P. IDJAO, MMPA***		***Chief Administrative Officer***		***Property and Supply Division***
SIGNATURE OVER PRINTED NAME		*POSITION*		*DEPARTMENT/DIVISION*

Section VII. Technical Specifications

Notes for Preparing the Technical Specifications

A set of precise and clear specifications is a prerequisite for Bidders to respond realistically and competitively to the requirements of the Procuring Entity without qualifying their Bids. In the context of Competitive Bidding, the specifications (*e.g.* production/delivery schedule, manpower requirements, and after-sales service/parts, descriptions of the lots or items) must be prepared to permit the widest possible competition and, at the same time, present a clear statement of the required standards of workmanship, materials, and performance of the goods and services to be procured. Only if this is done will the objectives of transparency, equity, efficiency, fairness, and economy in procurement be realized, responsiveness of bids be ensured, and the subsequent task of bid evaluation and post-qualification facilitated. The specifications should require that all items, materials and accessories to be included or incorporated in the goods be new, unused, and of the most recent or current models, and that they include or incorporate all recent improvements in design and materials unless otherwise provided in the Contract.

Samples of specifications from previous similar procurements are useful in this respect. The use of metric units is encouraged. Depending on the complexity of the goods and the repetitiveness of the type of procurement, it may be advantageous to standardize the General Technical Specifications and incorporate them in a separate subsection. The General Technical Specifications should cover all classes of workmanship, materials, and equipment commonly involved in manufacturing similar goods. Deletions or addenda should then adapt the General Technical Specifications to the particular procurement.

Care must be taken in drafting specifications to ensure that they are not restrictive. In the specification of standards for equipment, materials, and workmanship, recognized Philippine and international standards should be used as much as possible. Where other particular standards are used, whether national standards or other standards, the specifications should state that equipment, materials, and workmanship that meet other authoritative standards, and which ensure at least a substantially equal quality than the standards mentioned, will also be acceptable. The following clause may be inserted in the Special Conditions of Contract or the Technical Specifications.

Sample Clause: Equivalency of Standards and Codes

Wherever reference is made in the Technical Specifications to specific standards and codes to be met by the goods and materials to be furnished or tested, the provisions of the latest edition or revision of the relevant standards and codes shall apply, unless otherwise expressly stated in the Contract. Where such standards and codes are national or relate to a particular country or region, other authoritative standards that ensure substantial equivalence to the standards and codes specified will be acceptable.

Reference to brand name and catalogue number should be avoided as far as possible; where unavoidable they should always be followed by the words "*or at least equivalent*." References to brand names cannot be used when the funding source is the GOP.

Where appropriate, drawings, including site plans as required, may be furnished by the *University of the Philippines Manila – Philippine General Hospital* with the Bidding Documents. Similarly, the Supplier may be requested to
during contract execution.

Bidders are also required, as part of the technical specifications, to complete their statement of compliance demonstrating how the items comply with the specification.

Technical Specifications

Item	Specification	Statement of Compliance
		[Bidders must state here either "Comply" or "Not Comply" against each of the individual parameters of each Specification stating the corresponding performance parameter of the equipment offered. Statements of "Comply" or "Not Comply" must be supported by evidence in a Bidders Bid and cross-referenced to that evidence. Evidence shall be in the form of manufacturer's un-amended sales literature, unconditional statements of specification and compliance issued by the manufacturer, samples, independent test data etc., as appropriate. A statement that is not supported by evidence or is subsequently found to be contradicted by the evidence presented will render the Bid under evaluation liable for rejection. A statement either in the Bidder's statement of compliance or the supporting evidence that is found to be false either during Bid evaluation, post-qualification or the execution of the Contract may be regarded as fraudulent and render the Bidder or supplier liable for prosecution subject to the applicable laws and issuances.]

[Use this form for Framework Agreement:]

Technical Specifications

TECHNICAL SPECIFICATIONS			
Item No.	***Description***	***Quantity***	***Statement of Compliance***
			[Bidders must state here either "Comply" or "Not Comply" against each of the individual parameters of each Specification stating the corresponding performance parameter of the equipment offered. Statements of "Comply" or "Not Comply" must be supported by evidence in a Bidders Bid and cross-referenced to that evidence. Evidence shall be in the form of manufacturer's un-amended sales literature, unconditional statements of specification and compliance issued by the manufacturer, samples, independent test data etc., as appropriate. A statement that is not supported by evidence or is subsequently found to be contradicted by the evidence presented will render the Bid under evaluation liable for rejection. A statement either in the Bidder's statement of compliance or the supporting evidence that is found to be false either during Bid evaluation, post-qualification or the execution of the Contract may be regarded as fraudulent and render the Bidder or supplier liable for prosecution.]

TECHNICAL SPECIFICATIONS			
Item No.	***Description***	***Quantity***	***Statement of Compliance*** (***Comply / Did not Comply)***
1	Acetylcysteine 200mg/mL, 25mL vial/bottle (IV infusion)	720	
2	Aciclovir 25mg/mL, 10mL vial (IV infusion)	4,800	
3	Albumin Human 20%, 50mL bottle (IV, IV infusion)	3,144	
4	Adenosine 3 mg/mL, 2 mL vial (IV)	1,114	
5	Amikacin sulfate 125mg/mL , 2mL ampule/vial (IM, IV)	12,000	
6	Amikacin sulfate 250mg/mL , 2mL ampule/vial (IM, IV)	14,928	
7	Aminophylline (theophylline ethylenediamine) 25 mg/mL, 10 mL ampul (IV)	1,200	
8	Amiodarone hydrochloride 50 mg/mL, 3 mL ampul (IV)	5,750	
9	Amphotericin B non lipid complex 50mg lyophilized powder, vial (IV infusion)	720	
10	Amphotericin B Lipid Complex (as cholesteryl complex, colloidal dispersion) 50 mg vial (IV infusion)	1,440	
11	Ampicillin + Sulbactam 1000 mg ampicillin + 500 mg sulbactam (IM, IV) (as sodium salt) per vial	24,000	
12	Ampicillin + Sulbactam 500 mg ampicillin + 250 mg sulbactam (IM, IV) (as sodium salt) per vial	25,320	
13	Ampicillin sodium 250mg vial (IM, IV)	12,000	
14	Ampicillin sodium 500mg vial (IM, IV)	13,320	
15	Atracurium besilate 10mg/mL, 2.5mL ampule (IV)	16,380	
16	Atropine sulfate 1mg/mL, 1 mL ampul (IM, IV, SC)	20,170	
17	Azithromycin 500 mg powder, vial (IV infusion) (as base*/as dihydrate)	2,400	
18	Aztreonam 1g powder for injection (IV, IV Infusion)	2,400	
19	Basiliximab 20 mg vial (IV infusion)	13	

20	Beractant 25 mg/ml suspension, 8mL Intratracheal administration vial	240	
21	Beractant 25 mg/mL suspension, 4 mL Intratracheal administration vial	240	
22	Bleomycin sulfate powder, 15 IU ampul/vial (IM,IV)	360	
23	Bupivacaine Hydrochloride 0.5% 4 mL ampul (spinal) with 8% dextrose	8,280	
24	Bupivacaine Hydrochloride 0.5%, 10mL ampul/vial (local infiltration)	18,000	
25	Butorphanol tartrate 2 mg/mL, 1 mL ampul/vial (IM, IV)	2,655	
26	Calcium folinate (leucovorin Ca) 10mg/mL, 5mL ampule/vial (IM, IV)	6,940	
27	Calcium Gluconate 10%, 10 mL ampul/vial (IV)	25,470	
28	Carbetocin 100 mcg/mL, 1 mL ampule/vial, solution for Injection (IV)	6,120	
29	Carboprost 250 mcg/mL solution for injection, 1 mL ampule/vial	312	
30	Carboplatin 10mg/mL, 15mL vial (IV)	1,575	
31	Carboplatin 10mg/mL, 45mL vial (IV)	2,450	
32	Cefazolin sodium 1gm vial (IM, IV)	19,680	
33	Cefepime Hydrochloride 1gm vial (IM, IV)	4,800	
34	Cefepime Hydrochloride 2gms vial (IM, IV)	2,400	
35	Cefotaxime sodium 500 mg vial + 2 mL diluent (IM, IV)	2,400	
36	Ceftazidime pentahydrate 1gm vial (IM, IV)	17,748	
37	Ceftriaxone disodium/sodium 1gm vial + 10mL diluent (IV)	25,320	
38	Cefuroxime sodium 750mg vial (IM, IV)	19,680	
39	Ciprofloxacin lactate 2mg/mL, 100mL vial (IV infusion)	7,200	
40	Cisplatin 1mg/mL, 10mL vial (IV)	325	
41	Cisplatin 1mg/mL, 50mL vial (IV)	1,500	

42	Clindamycin phosphate 150mg/mL, 2mL ampule/vial (IM, IV)	25,320	
43	Clindamycin phosphate 150mg/mL, 4mL ampule (IM, IV)	24,000	
44	Colistin 2,000,000 IU lyophilized powder for injection (IV infusion)	1,090	
45	Cyclophosphamide 500mg vial powder (IV)	2,715	
46	Cyclophosphamide 1gm vial powder (IV)	2,715	
47	Cytarabine 100 mg/mL solution for injection, 1 mL	3,015	
48	Cytarabine 100 mg/mL solution for injection, 5 mL	2,115	
49	Cytarabine 100 mg/mL solution for injection, 10 mL	2,115	
50	Dacarbazine powder, 200mg vial (IV, IV infusion)	600	
51	Dactinomycin powder, 500 micrograms vial (IV)	440	
52	Dantrolene Sodium 20 mg (with mannitol 3g)/vial (for reconstitution with 60 mL sterile water for injection) (IV) (With Compassionate Special Permit)	396	
53	Deferoxamine mesilate powder, 500 mg vial (IM, IV infusion, SC)	2,460	
54	Dexamethasone sodium phoshate 4 mg/mL, 2 mL ampul/vial (IM, IV)	56,920	
55	Dexamethasone sodium phoshate 5mg/mL, 1mL ampule (IM, IV)	53,400	
56	Diazepam 5 mg/mL, 2 mL ampul (IM, IV) (With PDEA Permit)	990	
57	Digoxin 250 micrograms/mL, 2 mL ampul (IM, IV)	984	
58	Diphenhydramine Hydrochloride 50 mg/mL, 1 mL ampul (IM, IV)	20,770	
59	Dobutamine Hydrochloride 50mg/mL, 5ml ampule (IV infusion)	3,726	
60	Docetaxel anhydrous 20 mg/0.5 mL, 0.5 mL vial (IV infusion)	1,500	
61	Docetaxel anhydrous 40 mg/mL, 2 mL vial (IV infusion)	750	

62	Dopamine Hydrochloride 40mg/mL 5mL vial/ampule (IV)	3,720	
63	Doxorubicin Hydrochloride powder, 50mg vial or 2mg/mL, 25mL vial (IV)	3,750	
64	Enoxaparin sodium 100mg/mL, 0.4mL pre-filled syringe (SC)	24,300	
65	Enoxaparin sodium 100mg/mL, 0.6mL pre-filled syringe (SC)	15,000	
66	Ephedrine sulfate 50 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	3,300	
67	Epinephrine Hydrochloride 1mg/mL, 1mL ampule (IV, IM, SC)	64,100	
68	Epirubicin (as hydrochloride) powder, 50mg vial (IV)	75	
69	Epoetin alfa (recombinant human erythropoetin) 10,000 IU/mL, pre-filled syringe (IV, SC)	384	
70	Epoetin alfa (recombinant human erythropoetin) 4000 IU/0.4 mL, pre-filled syringe (IV, SC)	3,000	
71	Epoetin alfa (recombinant human erythropoietin) 2000 IU/0.5 mL, pre-filled syringe (IV, SC)	480	
72	Epoetin Beta (recombinant erythropoietin) 2000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	480	
73	Epoetin Beta (recombinant erythropoietin) 5000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	780	
74	Ertapenem sodium 1gm powder vial (IM/IV)	3,600	
75	Esmolol Hydrochloride 10mg/mL, 10mL vial (IV)	1,920	
76	Etoposide 20mg/mL, 5mL ampule/vial (IV)	1,500	
77	Famotidine 20 mg powder/lyophilized powder for injection, ampule/vial (IV)	2,640	
78	Fentanyl citrate 50mcg/mL, 2mL amp (IV) (With PDEA Permit)	39,756	
79	Filgrastim 150 micrograms/0.6 mL, vial (IV, SC)	615	
80	Fluconazole 2mg/mL, 100mL vial (IV infusion)	7,332	
81	Flumazenil 100 micrograms/mL, 5 mL ampul (slow IV, IV infusion)	269	

82	Fluphenazine (as decanoate) 25mg/mL, 1mL ampule (IM)	180	
83	Fluorescein (as sodium salt) 10% (100mg/mL), 5 mL ampul (IV)	720	
84	Fluorouracil 50 mg/mL, 10 mL ampul/vial (IV, IV infusion)	10,500	
85	Fondaparinux sodium 2.5 mg/0.5 mL solution (IV, SC)	180	
86	Furosemide 10 mg/mL, 2 mL ampul (IM, IV)	51,240	
87	Ganciclovir sodium 500 mg vial (IV infusion)	180	
88	Gemcitabine Hydrochloride 1gm vial (IV infusion)	810	
89	Gemcitabine Hydrochloride 200mg vial (IV infusion)	1,500	
90	Gentamicin sulfate 40mg/mL, 2mL ampule/vial (IM, IV)	26,184	
91	Glucose (dextrose) 50%, 50mL vial (IV)	18,636	
92	Glyceryl trinitrate (nitroglycerin) 1mg/mL, 10mL ampule (IV infusion)	7,440	
93	Goserelin acetate 10.8mg depot solution pre-filled syringe (SC)	72	
94	Goserelin acetate 3.6mg depot solution, pre-filled syringe (SC)	72	
95	Haloperidol 5 mg/mL, 1 mL ampul (IM)	1,200	
96	Heparin sodium unfractionated 1,000 iu/mL, 5mL vial (IV infusion, SC) (bovine origin)	5,040	
97	Heparin sodium unfractionated 5000 IU/mL, 5 mL vial (IV infusion, SC) (bovine origin)	5,592	
98	Human recombinant tissue type plasminogen activator (alteplase) 50 mg powder for I.V. infusion	60	
99	Hydralazine Hydrochloride 20 mg/mL, 1 mL ampul (IM, IV)	444	
100	Hydrocortisone sodium succinate 50mg/mL, 2mL vial or 100mg powder vial (IV)	9,120	
101	Hydrocortisone sodium succinate 125 mg/mL, 2 mL vial (IV) or 250 mg powder vial (IV)	4,800	

102	Hyoscine-n-butylbromide 20mg/mL, 1mL ampule (IM, IV, SC)	8,292	
103	Idarubicin (as hydrochloride) powder, 5 mg vial (IV)	60	
104	Ifosfamide powder, 2gms vial (IV infusion)	2,500	
105	Ifosfamide powder, 1g vial (IV infusion)	2,500	
106	Insulin, regular(recombinant DNA human) 100 IU/mL, 10mL vial (SC, IV/IM)	1,464	
107	Insulin, Biphasic Isophane Human 70/30 (recombinant DNA) 70% isophane suspension + 30% soluble insulin in 100 IU/mL, 10 mL vial (SC)	720	
108	Isophane Insulin Human (recombinant DNA) 100 IU/mL, 10 mL vial (SC)	1,440	
109	Isosorbide dinitrate 1mg/ml, 10mL ampule (IV)	1,392	
110	Iron sucrose 20mg/mL, 5mL ampule (IV, IV infusion)	5,800	
111	Isoxsuprine hydrochloride 5 mg/mL, 2 mL ampul (IM, IV infusion)	480	
112	Ketamine hydrochloride 50 mg/mL, 10 mL vial (IM, IV) (With PDEA Permit)	409	
113	Ketorolac tromethamol 30 mg/mL, 1 mL ampul (IM, IV)	53,100	
114	Levetiracetam 500 mg/5 mL (100 mg/mL) concentrate solution for IV infusion, 5 mL vial	5,064	
115	Levofloxacin 5 mg/mL solution for IV infusion, 100mL vial	7,200	
116	Lidocaine Hydrochloride 2%, 5mL ampule/vial (IM/IV)	51,200	
117	Lidocaine Hydrochloride 2%, 50mL ampule/vial (IM, IV)	10,080	
118	Lidocaine Hydrochloride 2%, 1.8 mL carpule (with epinephrine) (local infiltration)	2,400	
119	Linezolid 2 mg/mL (600 mg/300 mL), solution for infusion (IV)	1,440	
120	Magnesium sulfate heptahydrate 250mg/mL, 20mL vial (IV)	9,456	

121	Mesna (sodium-2mercapto ethanesulphonate) 100mg/mL, 4mL ampule (IV)	5,640	
122	Methotrexate 25 mg/mL, 2 mL ampul/vial (IM, IV, Intrathecal) (as base)	4,680	
123	Methotrexate sodium 100mg/mL, 10mL vial (IM, IV, Intrathecal) (preservative free)	630	
124	Methylergometrine (methylergonovine) (as hydrogen maleate or maleate) 200 micrograms/mL, 1 mL ampul (IM, IV)	339	
125	Methylprednisolone 40 mg in single dose vial, solution for injection (IV, IM) (as sodium succinate)	1,440	
126	Methylprednisolone lyophilized powder, 500 mg vial (IM, IV) (as sodium succinate)	1,359	
127	Metoclopramide 5mg/mL, 2mL ampule (As Base and As Hydrochloride) (IM/IV)	16,880	
128	Metronidazole 5 mg/mL, 100 mL vial (IV infusion)	13,056	
129	Midazolam 1mg/mL, 5mL ampule or 5mg/mL, 1mL ampule (IM, IV) (With PDEA Permit)	9,042	
130	Midazolam 5mg/mL, 3mL ampule (IM, IV) (With PDEA Permit)	11,346	
131	Milrinone 10mg/ml, 10ml ampule (IV) (With Compassionate Special Permit)	5,064	
132	Morphine Sulfate 10 mg/mL, 1 mL ampul (IM, IV, SC) or 16 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	5,472	
133	Nalbuphine Hydrochloride 10 mg/mL, 1 mL ampul (IM, IV, SC) (With PDEA Permit)	2,394	
134	Naloxone hydrochloride 400 micrograms/mL, 1 mL ampul (IM, IV, SC)	1,440	
135	Neostigmine 500 mcg/mL solution for injection (IM/IV/SC), 1 mL ampule	18,830	
136	Nicardipine Hydrochloride 1mg/mL, 2mL ampule (IV)	1,320	
137	Norepinephrine bitartrate 1mg/mL, 2mL ampule (IV infusion)	48,000	
138	Norepinephrine bitartrate 1mg/mL, 4mL ampule (IV infusion)	50,640	

139	Norepinephrine bitartrate 2 mg /mL, 4 mL ampule (8 mg/4 mL) solution for injection	1,000	
140	Octreotide acetate 100 micrograms/mL ampul (IV infusion)	3,840	
141	Omeprazole powder, 40 mg vial + 10 mL solvent ampul/vial (IV)	50,520	
142	Ondansetron 2mg/mL, 2mL ampule (IM, IV)	9,000	
143	Ondansetron 2mg/mL, 4mL ampule (IM, IV)	26,220	
144	Oxacillin sodium 500mg vial (IM, IV)	25,320	
145	Oxaliplatin 50mg vial powder (IV Infusion)	6,000	
146	Oxytocin (synthetic) 10 IU/mL, 1 mL ampul (IM, IV)	9,820	
147	Paclitaxel 6mg/mL, 16.7mL vial or 17mL vial (IV, IV infusion) (with special IV line)	2,500	
148	Paclitaxel 6mg/mL, 25mL vial (IV, IV infusion) (with special IV line)	1,500	
149	Paclitaxel 6mg/mL, 43.4mL vial (IV, IV infusion) (with special IV line)	1,650	
150	Paracetamol 150mg/mL, 2mL ampule solution for injection (IM, IV)	150,550	
151	Paracetamol 10 mg/mL, 50 mL vial solution for infusion (IV)	7,812	
152	Paracetamol 10 mg/mL, 100 mL vial solution for infusion (IV)	8,160	
153	Penicillin G benzathine (benzathine benzylpenicillin) 1,200,000 units vial (MR) (IM)	2,400	
154	Penicillin G crystalline (benzylpenicillin) sodium 1,000,000 units vial (IM, IV)	7,464	
155	Penicillin G crystalline (benzylpenicillin) sodium 5,000,000 units vial (IM, IV)	2,664	
156	Pethidine (meperidine) (as hydrochloride) 50 mg/mL, 2 mL ampul (IM, IV, SC) (With PDEA Permit)	5,500	
157	Phenylephrine hydrochloride 10mg/1mL vial (With Compassionate Special Permit) (IV/IV Infusion)	2,640	
158	Phenytoin sodium 50mg/mL, 2mL ampule (IV)	2,400	

159	Phytomenadione (phytonadione, vitamin K1) 10mg/mL, 1mL ampul (IM, IV, SC) (as mixed micelle)	9,528	
160	Polymyxin B sulfate 500,000 Units powder for solution for injection (Intrathecal/IM/IV), 5 mL vial	13,420	
161	Potassium chloride 2meq/mL, 20mL vial (IV infusion)	11,196	
162	Propofol 10mg/mL, 20mL ampule/vial (IV)	18,856	
163	Protamine sulfate 10mg/mL, 5mL ampule (IV) (With Compassionate Special Permit)	1,335	
164	Ranitidine hydrochloride 25 mg/mL, 2 mL ampul/vial (IM, IV, IV infusion)	12,264	
165	Remifentanil 1mg lyophilized powder vial (IV Infusion) (With PDEA Permit)	1,980	
166	Rituximab 10mg/mL, 50mL vial (IV)	150	
167	Rituximab 10mg/mL, 10mL vial (IV)	50	
168	Rocuronium bromide 10 mg/mL, 5 mL ampul/vial (IV)	4,314	
169	Ropivacaine Hydrochloride 10mg/mL, 10mL ampule (IV)	2,640	
170	Sodium Bicarbonate 1 mEq/mL, 20 mL ampul/vial (adult) (IV infusion)	15,000	
171	Sodium bicarbonate 1mEq/mL, 50mL ampul/vial (adult) (IV infusion)	11,500	
172	Sodium Chloride 2.5mEq/mL, 20mL vial	7,728	
173	Somatostatin 3mg ampule/vial (IV, IV infusion)	195	
174	Sugammadex 100 mg/mL solution for injection (IV), 2 mL vial	2,945	
175	Suxamethonium (succinylcholine) chloride 20 mg/mL, 10 mL vial (IV)	2,883	
176	Terbutaline sulfate 500mcg/mL, 1mL ampule (IM, IV, SC)	768	
177	Tramadol Hydrochloride 50mg/mL, 1mL ampule (IM, IV, SC)	25,260	
178	Tramadol Hydrochloride 50mg/mL, 2mL ampule (IM, IV, SC)	13,320	

179	Tranexamic acid 100mg/mL, 5mL ampule (IM, IV)	40,260	
180	Trastuzumab 150 mg lyophilized powder (IV infusion) vial	3,415	
181	Trastuzumab 600 mg/5 mL (120 mg/mL) solution for injection (SC), 5 mL vial	650	
182	Valproic Acid 500 mg/ 5mL IV infusion, 5 mL vial	50	
183	Vasopressin 20 IU/mL (IM, IV)	2,664	
184	Verapamil Hydrochloride 2.5 mg/mL, 2 mL ampul (IV)	372	
185	Vinblastine sulfate 1 mg/mL, 10 mL vial (IV)	300	
186	Vincristine sulfate 1 mg/mL, 1 mL vial (IV)	1,300	
187	Vincristine sulfate 1 mg/mL, 2 mL vial (IV)	1,420	
188	Vitamin B1 B6 B12 100 mg B1 + 100 mg B6 + 1 mg B12 per 3 mL ampul (IV)	300	
189	Voriconazole 200mg lyophilized powder for solution for IV infusion, 30mLVial	600	
TOTAL APPROVED BUDGET FOR THE CONTRACT:			***PhP625,712,164.01***
TERMS AND CONDITIONS			
1. Indicate the **brand and packing of the item/s** offered.			
2. The brand offered must be **at least five (5) years commercially available in the market from date of opening of bids.** Proof of this shall be the initial Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).			
3. **Submit the following documents, submission should be per product, with tab and per item number. Two (2) copies for the Valid Certificate of Product Registration and Certificate of Analysis (COA).**			
3.1. Memorandum of Agreement (MOA) and Certificate of exclusive/authorized distributorship between the manufacturer and distributor. Distributors/suppliers must have certification from their principals that they are the exclusive distributor of the drug products authorized to submit tender for the product on behalf of the principal and that all commitments made by them shall be honored by the principal in case of termination of distributorship agreement.			
3.2. Valid Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA). • **The name of the respective distributor should appear in the submitted CPR of the drug**.			

Note: *CPRs that will expire within three (3) months from the date of opening of bids should present the Official Receipt of renewal of application with the Document Tracking log for the CPR from the FDA.*	
3.3. Certificate of Analysis (COA) for the products offered (batch to be delivered if awarded) duly issued by an FDA accredited laboratory (local) and should contain information indicated in monograph of the drug. Sample analyzed must not be expired during the time of bidding. The result of assay submitted must be in the specific brand and should be in the exact dosage formulation of the drug being bidded. In cases where local laboratories are unavailable to perform drug assays, assays done abroad is accepted. The local COA is preferred and given more weight in the evaluation and awarding process.	
3.4. A notarized certificate that it is the innovator drug (if applicable).	
3.5. Certificate of Current Good Manufacturing Practice (CGMP).	
3.6. Valid License to Operate (LTO).	
3.7. A notarized certificate that the offered brand has not been subject to product complaint/product recall for the past three (3) years.	
3.8. Certificate of Acceptance from at least three (3) major hospital issued within the year and should be supported with Sales Invoice (*for new item/brand offered only)*.	
3.9. A notarized certificate that there are sufficient stocks for the offered item/s for one (1) year.	
4. The offered drug must conform to the latest Philippine Food and Drug Administration (FDA) Administrative Order **governing the generic labeling and packaging requirements.**	
4.1 For all tablets and capsules	
4.1.1 **All tablets/capsules should be in foil or blister pack. A picture of the blister pack (front and back) should be submitted.**	
4.1.2 Each individual flap in the tablet or capsule blister pack should be labeled with the generic name and brand.	
4.1.3 Dosage form and strength of the Active Pharmaceutical Ingredients (API) should appear on each unit or every 2 units for products with multiple APIs.	
4.1.4 Name of drug, lot or batch number and expiry date must appear on every standard blister pack/foil strip and on the container or inner packing. However, if the product is not restricted for dispensing in quantities less than the standard blister pack or foil strip, the batch or lot number and expiry date should appear on each unit.	
4.1.5. Inner label must be the same as the outer label.	

4.1.6 A complete drug literature/product insert must accompany the product.	
5. The following must be complied with specific for **cytotoxic injectable drugs.**	
5.1. For cytotoxic injectable drugs, winning bidders are required to *provide Material Safety Data Sheet (MSDS) and to submit Drug Profile* to the Pharmacy Department per company under the first Purchase Order.	
5.2. Winning bidders for cytotoxic injectable drugs are required to **provide at least three (3) spill kits** per company under the first Purchase Order.	
6. The brand offered on all antibiotics must have stability that is equivalent to that of the innovator product or better.	
7. **New brands offered** shall be subject to further evaluation and shall require the following:	
7.1. Validation of the submitted Certificate of Acceptance from at least three (3) major hospitals	
7.2. Justification from end-user/s to validate the acceptance of the good/s offered (to be facilitated by PGH-PSD).	
8. **For the supply and delivery of awarded drugs and medicines.**	
8.1 Delivery of the goods is required as stated in the request of the end-user, commencing on the 3rd working day of notification through confirmed fax/email that the approved Call-off/ Notice to Supplier (NTS) is already available for pick up.	
8.2 Delivery schedule (whichever is applicable): 8.1.1 within seven (7) calendar days; 8.1.2 as may be called for; 8.1.3 staggered delivery within three (3) months * 50% of the total quantity within seven (7) calendar days and 25% each for the succeeding months *Note: The end-user has the right to adjust the quantity to be delivered depending on the actual need of the hospital*	
8.3 Deliveries shall have at least two (2) years expiration date.	
8.4 Delivery of goods **with product complaint shall be put on hold** until receipt of the final decision of the PGH management whether to proceed with the acceptance or to cancel/return the items	

8.5 Delivered **items found to be non-formulary at any given time shall be returned** to the company and a credit memo shall be issued.	
8.6 Stocks delivered **are subject to random sampling for testing** as to quality and conformity to label. Testing fee at supplier's expense.	
8.7 Stocks with lot #/batch different from the submitted Certificate of Analysis (COA) will be subjected to testing as to quality and conformity to label. Testing fee at supplier's expense.	
8.8 All items that had been pulled out for various reasons, a credit memo shall be issued by the Contractor within one (1) month, otherwise, a debit memo shall be processed by UP Manila - PGH and the amount will be deducted from any amount due to Supplier.	
8.9 It is understood that the Supplier is legally responsible to deliver all issued **CALL-OFF/s** (Purchase Order) and **failure to deliver the first Call-Off as scheduled shall mean automatic cancellation of the Call-Off and Notice to Execute Framework Agreement (NEFA).** Purchase from other source for whatever means shall be effected immediately to provide the requirements of the hospital. Penalty to the defaulting contractor shall be charged accordingly.	
9. **Failure to comply with the submission of the required documents shall be ground for post-disqualification in accordance with RA 9184.**	
10. Compliance with RA 9184 and other applicable laws.	

I hereby certify to comply and deliver all the above requirements

_____
Name of Company/ Bidder

_____
Signature over Printed Name of Representative

_____
Date

Section VIII. Checklist of Technical and Financial Documents

Notes on the Checklist of Technical and Financial Documents

The prescribed documents in the checklist are mandatory to be submitted in the Bid, but shall be subject to the following:

a. GPPB Resolution No. 09-2020 on the efficient procurement measures during a State of Calamity or other similar issuances that shall allow the use of alternate documents in lieu of the mandated requirements; or

b. Any subsequent GPPB issuances adjusting the documentary requirements after the effectivity of the adoption of the PBDs.

The BAC shall be checking the submitted documents of each Bidder against this checklist to ascertain if they are all present, using a non-discretionary "pass/fail" criterion pursuant to Section 30 of the 2016 revised IRR of RA No. 9184.

Checklist of Technical and Financial Documents

I. TECHNICAL COMPONENT ENVELOPE

Class "A" Documents

Legal Documents

☐ (a) Valid PhilGEPS Registration Certificate (Platinum Membership) (all pages);

☐ (b) Registration certificate from Securities and Exchange Commission (SEC), Department of Trade and Industry (DTI) for sole proprietorship, or Cooperative Development Authority (CDA) for cooperatives or its equivalent document,

☐ (c) Mayor's or Business permit issued by the city or municipality where the principal place of business of the prospective bidder is located, or the equivalent document for Exclusive Economic Zones or Areas;

☐ (d) Tax clearance per E.O. No. 398, s. 2005, as finally reviewed and approved by the Bureau of Internal Revenue (BIR).

☐ (e) Notarized UP Questionnaire

Technical Documents

☐ (f) Statement of the prospective bidder of all its ongoing government and private contracts, including contracts awarded but not yet started, if any, whether similar or not similar in nature and complexity to the contract to be bid;

☐ (g) Statement of the bidder's Single Largest Completed Contract (SLCC) similar to the contract to be bid, except under conditions provided for in Sections 23.4.1.3 and 23.4.2.4 of the 2016 revised IRR of RA No. 9184, within the relevant period as provided in the Bidding Documents;

☐ (h) Original copy of Bid Security. If in the form of a Surety Bond, submit also a certification issued by the Insurance Commission;

or

Original copy of Notarized Bid Securing Declaration;

☐ (i) Conformity with the Technical Specifications, which may include production/delivery schedule, manpower requirements, and/or after-sales/parts, if applicable;

☐ (j) Original duly signed Omnibus Sworn Statement (OSS);

and if applicable, Original Notarized Secretary's Certificate in case of a corporation, partnership, or cooperative; or Original Special Power of Attorney of all members of the joint venture giving full power and authority to its officer to sign the OSS and do acts to represent the Bidder.

Financial Documents

☐ (k) The Supplier's audited financial statements, showing, among others, the Supplier's total and current assets and liabilities, stamped "received" by the BIR or its duly accredited and authorized institutions, for the preceding calendar year which should not be earlier than two (2) years from the date of bid submission;

☐ (l) The prospective bidder's computation of Net Financial Contracting Capacity (NFCC);

or

A committed Line of Credit from a Universal or Commercial Bank in lieu of its NFCC computation.

Class "B" Documents

☐ (m) If applicable, a duly signed joint venture agreement (JVA) in case the joint venture is already in existence;

or

duly notarized statements from all the potential joint venture partners stating that they will enter into and abide by the provisions of the JVA in the instance that the bid is successful.

Other documentary requirements under RA No. 9184 (as applicable)

☐ (n) *[For foreign bidders claiming by reason of their country's extension of reciprocal rights to Filipinos]* Certification from the relevant government office of their country stating that Filipinos are allowed to participate in government procurement activities for the same item or product.

☐ (o) Certification from the DTI if the Bidder claims preference as a Domestic Bidder or Domestic Entity.

25 FINANCIAL COMPONENT ENVELOPE

☐ (a) Original of duly signed and accomplished Financial Bid Form;

☐ (b) Original of duly signed and accomplished Price Schedule(s); **and**

☐ (c) Original of duly signed and accomplished Price Schedule (Annex)

Bid Form

Date: _____
Project Reference No.: _____

THE BIDS AND AWARDS COMMITTEE 1
UPM – Philippine General Hospital
Taft Avenue, Manila

Gentlemen and/or Ladies:

Having examined the Philippine Bidding Documents (PBDs) including the Supplemental or Bid Bulletin Numbers *[insert numbers]*, the receipt of which is hereby duly acknowledged, we, the undersigned, offer to *[supply/deliver/perform] [description of the Goods]* in conformity with the said PBDs for the sum of *[total Bid amount in words and figures]* or the total calculated bid price, as evaluated and corrected for computational errors, and other bid modifications in accordance with the Price Schedules attached herewith and made part of this Bid. The total bid price includes the cost of all taxes, such as, but not limited to: *[specify the applicable taxes, e.g. (i) value added tax (VAT), (ii) income tax, (iii) local taxes, and (iv) other fiscal levies and duties]*, which are itemized herein or in the Price Schedules,

If our Bid is accepted, we undertake:

a. to deliver the goods in accordance with the delivery schedule specified in the Schedule of Requirements of the Philippine Bidding Documents (PBDs);

b. to provide a performance security in the form, amounts, and within the times prescribed in the PBDs;

c. to abide by the Bid Validity Period specified in the PBDs and it shall remain binding upon us at any time before the expiration of that period.

[Insert this paragraph if Foreign-Assisted Project with the Development Partner:
Commissions or gratuities, if any, paid or to be paid by us to agents relating to this Bid, and to contract execution if we are awarded the contract, are listed below:

Name and address of agent	Amount and Currency	Purpose of Commission or gratuity

(if none, state "None") *]*

Until a formal Contract is prepared and executed, this Bid, together with your written acceptance thereof and your Notice of Award, shall be binding upon us.

We understand that you are not bound to accept the Lowest Calculated Bid or any Bid you may receive.

We certify/confirm that we comply with the eligibility requirements pursuant to the PBDs.

The undersigned is authorized to submit the bid on behalf of *[name of the bidder]* as evidenced by the attached *[state the written authority]*.

We acknowledge that failure to sign each and every page of this Bid Form, including the attached Schedule of Prices, shall be a ground for the rejection of our bid.

Name: _____

Legal capacity: _____

Signature: _____

Duly authorized to sign the Bid for and behalf of: _____

Date: _____

Price Schedule for Goods Offered from Abroad

[shall be submitted with the Bid if bidder is offering goods from Abroad]

For Goods Offered from Abroad

Name of Bidder: _____ Project Reference No._____ Page ___ of ___

1	2	3	4	5	6	7	8	9	10
Item	Description	Brand Name	Country of origin	Quantity	Unit price CIF port of entry (specify port) or CIP named place (specify border point or place of destination)	Total CIF or CIP price per item (col. 5 x 6)	Unit Price Delivered Duty Unpaid (DDU)	Unit price Delivered Duty Paid (DDP)	Total Price delivered DDP (col 5 x 9)

Name: _____

Legal Capacity: _____

Signature: _____

Duly authorized to sign the Bid for and behalf of: _____

Price Schedule for Goods Offered from Within the Philippines

[shall be submitted with the Bid if bidder is offering goods from within the Philippines]

For Goods Offered from Within the Philippines

Name of Bidder _____ Project Ref No._____ Page ___of___

1	2	3	4	5	6	7	8	9	10	11
Item	Description	Brand Name	Country of origin	Quantity	Unit price EXW per item	Transportation and all other costs incidental to delivery, per item	Sales and other taxes payable if Contract is awarded, per item	Cost of Incidental Services, if applicable, per item	Total Price, per unit (col 6=7=8=9)	Total Price delivered Final Destination (col 10) x (col 5)

Name: _____

Legal Capacity: _____

Signature: _____

Duly authorized to sign the Bid for and behalf of: _____

Contract Agreement

THIS AGREEMENT made the _____ day of _____ 20_____ between [name of PROCURING ENTITY] of the Philippines (hereinafter called "the Entity") of the one part and [name of Supplier] of [city and country of Supplier] (hereinafter called "the Supplier") of the other part;

WHEREAS, the Entity invited Bids for certain goods and ancillary services, particularly [brief description of goods and services] and has accepted a Bid by the Supplier for the supply of those goods and services in the sum of *[contract price in words and figures in specified currency]* (hereinafter called "the Contract Price").

NOW THIS AGREEMENT WITNESSETH AS FOLLOWS:

1. In this Agreement words and expressions shall have the same meanings as are respectively assigned to them in the Conditions of Contract referred to.

2. The following documents as required by the 2016 revised Implementing Rules and Regulations of Republic Act No. 9184 shall be deemed to form and be read and construed as integral part of this Agreement, *viz.*:

   i. Philippine Bidding Documents (PBDs);
      i. Schedule of Requirements;
      ii. Technical Specifications;
      iii. General and Special Conditions of Contract; and
      iv. Supplemental or Bid Bulletins, if any

   ii. Winning bidder's bid, including the Eligibility requirements, Technical and Financial Proposals, and all other documents or statements submitted;

      Bid form, including all the documents/statements contained in the Bidder's bidding envelopes, as annexes, and all other documents submitted (*e.g.*, Bidder's response to request for clarifications on the bid), including corrections to the bid, if any, resulting from the Procuring Entity's bid evaluation;

   iii. Performance Security;

   iv. Notice of Award of Contract; and the Bidder's conforme thereto; and

   v. Other contract documents that may be required by existing laws and/or the Procuring Entity concerned in the PBDs. **Winning bidder agrees that additional contract documents or information prescribed by the GPPB that are subsequently required for submission after the contract execution, such as the Notice to Proceed, Variation Orders, and Warranty Security, shall likewise form part of the Contract.**

3. In consideration for the sum of *[total contract price in words and figures]* or such other sums as may be ascertained, *[Named of the bidder]* agrees to *[state the object of the contract]* in accordance with his/her/its Bid.

4. The *[Name of the procuring entity]* agrees to pay the above-mentioned sum in accordance with the terms of the Bidding.

IN WITNESS whereof the parties hereto have caused this Agreement to be executed in accordance with the laws of the Republic of the Philippines on the day and year first above written.

[Insert Name and Signature] *[Insert Signatory's Legal Capacity]* *for:* *[Insert Procuring Entity]*	*[Insert Name and Signature]* *[Insert Signatory's Legal Capacity]* *for:* *[Insert Name of Supplier]*

Acknowledgment

[Format shall be based on the latest Rules on Notarial Practice]

Omnibus Sworn Statement

REPUBLIC OF THE PHILIPPINES)
CITY/MUNICIPALITY OF _____) S.S.

A F F I D A V I T

I, [Name of Affiant], of legal age, [Civil Status], [Nationality], and residing at [Address of Affiant], after having been duly sworn in accordance with law, do hereby depose and state that:

1. *[Select one, delete the other:]*

   [If a sole proprietorship:] I am the sole proprietor or authorized representative of [Name of Bidder] with office address at [address of Bidder];

   [If a partnership, corporation, cooperative, or joint venture:] I am the duly authorized and designated representative of [Name of Bidder] with office address at [address of Bidder];

2. *[Select one, delete the other:]*

   [If a sole proprietorship:] As the owner and sole proprietor, or authorized representative of [Name of Bidder], I have full power and authority to do, execute and perform any and all acts necessary to participate, submit the bid, and to sign and execute the ensuing contract for [Name of the Project] of the [Name of the Procuring Entity], as shown in the attached duly notarized Special Power of Attorney;

   [If a partnership, corporation, cooperative, or joint venture:] I am granted full power and authority to do, execute and perform any and all acts necessary to participate, submit the bid, and to sign and execute the ensuing contract for [Name of the Project] of the [Name of the Procuring Entity], as shown in the attached [state title of attached document showing proof of authorization (e.g., duly notarized Secretary's Certificate, Board/Partnership Resolution, or Special Power of Attorney, whichever is applicable;)];

3. [Name of Bidder] is not "blacklisted" or barred from bidding by the Government of the Philippines or any of its agencies, offices, corporations, or Local Government Units, foreign government/foreign or international financing institution whose blacklisting rules have been recognized by the Government Procurement Policy Board, **by itself or by relation, membership, association, affiliation, or controlling interest with another blacklisted person or entity as defined and provided for in the Uniform Guidelines on Blacklisting;**

4. Each of the documents submitted in satisfaction of the bidding requirements is an authentic copy of the original, complete, and all statements and information provided therein are true and correct;

5. [Name of Bidder] is authorizing the Head of the Procuring Entity or its duly authorized

representative(s) to verify all the documents submitted;

6. *[Select one, delete the rest:]*

   [If a sole proprietorship:] The owner or sole proprietor is not related to the Head of the Procuring Entity, members of the Bids and Awards Committee (BAC), the Technical Working Group, and the BAC Secretariat, the head of the Project Management Office or the end-user unit, and the project consultants by consanguinity or affinity up to the third civil degree;

   [If a partnership or cooperative:] None of the officers and members of *[Name of Bidder]* is related to the Head of the Procuring Entity, members of the Bids and Awards Committee (BAC), the Technical Working Group, and the BAC Secretariat, the head of the Project Management Office or the end-user unit, and the project consultants by consanguinity or affinity up to the third civil degree;

   [If a corporation or joint venture:] None of the officers, directors, and controlling stockholders of *[Name of Bidder]* is related to the Head of the Procuring Entity, members of the Bids and Awards Committee (BAC), the Technical Working Group, and the BAC Secretariat, the head of the Project Management Office or the end-user unit, and the project consultants by consanguinity or affinity up to the third civil degree;

7. *[Name of Bidder]* complies with existing labor laws and standards; and

8. *[Name of Bidder]* is aware of and has undertaken the responsibilities as a Bidder in compliance with the Philippine Bidding Documents, which includes:

   a. Carefully examining all of the Bidding Documents;
   b. Acknowledging all conditions, local or otherwise, affecting the implementation of the Contract;
   c. Making an estimate of the facilities available and needed for the contract to be bid, if any; and
   d. Inquiring or securing Supplemental/Bid Bulletin(s) issued for the *[Name of the Project]*.

9. *[Name of Bidder]* did not give or pay directly or indirectly, any commission, amount, fee, or any form of consideration, pecuniary or otherwise, to any person or official, personnel or representative of the government in relation to any procurement project or activity.

10. **In case advance payment was made or given, failure to perform or deliver any of the obligations and undertakings in the contract shall be sufficient grounds to constitute criminal liability for Swindling (Estafa) or the commission of fraud with unfaithfulness or abuse of confidence through misappropriating or converting any payment received by a person or entity under an obligation involving the duty to deliver certain goods or services, to the prejudice of the public and the government of the Philippines pursuant to Article 315 of Act No. 3815 s. 1930, as amended, or the Revised Penal Code.**

IN WITNESS WHEREOF, I have hereunto set my hand this __ day of ___, 20__ at _____, Philippines.

[Insert NAME OF BIDDER OR ITS AUTHORIZED REPRESENTATIVE]
[Insert signatory's legal capacity]
Affiant

[Jurat]
[Format shall be based on the latest Rules on Notarial Practice]

Bank Guarantee Form for Advance Payment

THE BIDS AND AWARDS COMMITTEE 1
UPM – Philippine General Hospital
Taft Avenue, Manila

Name of Contract: _____
_____
_____
under Project Reference No. **BAC1-2022-10-0068-A**

Gentlemen and/or Ladies:

In accordance with the payment provision included in the Special Conditions of Contract, which amends Clause 2 **Error! Reference source not found.**of the General Conditions of Contract to provide for advance payment, *[name and address of Supplier]* (hereinafter called the "Supplier") shall deposit with the PROCURING ENTITY a bank guarantee to guarantee its proper and faithful performance under the said Clause of the Contract in an amount of *[amount of guarantee in figures and words]*.

We, the *[bank or financial institution]*, as instructed by the Supplier, agree unconditionally and irrevocably to guarantee as primary obligator and not as surety merely, the payment to the PROCURING ENTITY on its first demand without whatsoever right of objection on our part and without its first claim to the Supplier, in the amount not exceeding *[amount of guarantee in figures and words]*.

We further agree that no change or addition to or other modification of the terms of the Contract to be performed there under or of any of the Contract documents which may be made between the PROCURING ENTITY and the Supplier, shall in any way release us from any liability under this guarantee, and we hereby waive notice of any such change, addition, or modification.

This guarantee shall remain valid and in full effect from the date of the advance payment received by the Supplier under the Contract until *[date]*.

Yours truly,

Signature and seal of the Guarantors

_____
[name of bank or financial institution]

_____
[address]

_____
[date]

Bid Securing Declaration Form

REPUBLIC OF THE PHILIPPINES)
CITY OF _____) S.S.

x----------x

BID SECURING DECLARATION
Project Reference No.:_____

BIDS AND AWARDS COMMITTEE 1
UPM-Philippine General Hospital
Taft Avenue, Manila

I/We, the undersigned, declare that:

1. I/We understand that, according to your conditions, bids must be supported by a Bid Security, which may be in the form of a Bid Securing Declaration.

2. I/We accept that: (a) I/we will be automatically disqualified from bidding for any procurement contract with any procuring entity for a period of two (2) years upon receipt of your Blacklisting Order; and, (b) I/we will pay the applicable fine provided under Section 6 of the Guidelines on the Use of Bid Securing Declaration, within fifteen (15) days from receipt of the written demand by the procuring entity for the commission of acts resulting to the enforcement of the bid securing declaration under Sections 23.1(b), 34.2, 40.1 and 69.1, except 69.1(f),of the IRR of RA No. 9184; without prejudice to other legal action the government may undertake.

3. I/We understand that this Bid Securing Declaration shall cease to be valid on the following circumstances:

    a. Upon expiration of the bid validity period, or any extension thereof pursuant to your request;
    b. I am/we are declared ineligible or post-disqualified upon receipt of your notice to such effect, and (i) I/we failed to timely file a request for reconsideration or (ii) I/we filed a waiver to avail of said right; and
    c. I am/we are declared the bidder with the Lowest Calculated Responsive Bid, and I/we have furnished the performance security and signed the Contract.

IN WITNESS WHEREOF, I/We have hereunto set my/our hand/s this ____ day of *[month] [year]* at *[place of execution]*.

[Insert NAME OF BIDDER OR ITS AUTHORIZED REPRESENTATIVE]
[Insert signatory's legal capacity]
Affiant

[Jurat]
[Format shall be based on the latest Rules on Notarial Practice]

NFCC Computation

Project Reference No.: _____

ABC: _____

Kindly supply the required information in the spaces provided.

Name of Bidder: _____

DETAILS	AMOUNT
Current Assets	
Minus	
Current Liabilities	
Difference of Current Assets and Current Liabilities	
Multiplied by	
K	15
Total (Product)	
Minus	
Total amount of the Value of Outstanding Contracts	
Total NFCC Computation	

_____ _____

[signature] *[in the capacity of]*

Duly authorized to sign Bid for and on behalf of _____

Joint Venture Agreement

KNOWN ALL BY THESE PRESENTS:

That this JOINT VENTURE AGREEMENT is entered into By and Between _____, of legal age, _____, owner/proprietor of _____
(civil status)
and a resident of _____.

-and-

_____, of legal age, _____,
(civil status)
owner/proprietor of _____ a resident of _____.

That both parties agree to join together their manpower, equipment, and what is need to facilitate the Joint Venture to participate in the Eligibility, Bidding and Undertaking of the here-under stated project to be conducted by the University of the Philippines Manila/Philippine General Hospital.

NAME OF PROJECT CONTRACT AMOUNT

That both parties agree to jointly and severely liable for the entire assignment.

That both parties agree that _____ and/or _____ shall be the Official Representative of the Joint Venture, and is granted full power and authority to do, execute and perform any and all acts necessary and /or to represent the Joint Venture in the bidding as fully and effectively and the Joint Venture may do and if personally present with full power of substitution and revocation.

That this Venture Agreement shall remain in effect only for the above stated Projects until terminated by both parties.

Done this ___ day of _____, in the year of the Lord _____

_____
(Name of Company)
_____
(Address of the Company)
_____
(Telephone & Fax of the Company)
_____
(Website Address of the Company)
_____
(e-Mail Address of the Company)

_____
(Date of Issuance)

Letter of Acceptance

This is to certify that _____ has satisfactorily delivered
(Name of Bidder)

_____
(Item Description)

under P.O. No/s. _____ with Sales Invoice No. _____ and accepted on _____. Said company has no more pending obligation with us regarding their delivery/ies.

_____
(Signature over Printed Name)

_____
(Position)

_____
(Company Name)

University of the Philippines
Diliman, Quezon City

Questionnaire for Prospective Bidders
(additional requirement for eligibility)

1. Have you ever participated in any bidding in the University of the Philippines System?

YES	NO

If YES, fill up the table below. Use additional pages if necessary.

Constituent University/UP Campus	Name of the Project	Amount of Project	Duration Start/End (Dates)	Status (On-going/ Completed)

2. Has your company ever been suspended or blacklisted by the University of the Philippines System?

YES	NO

If YES, fill up the table below. Use additional pages if necessary.

Constituent University/UP Campus	Name of the Project	Reason for suspension/ blacklisting	Status (On-going/ Completed)

3. Has your company ever been suspended or blacklisted by any government agency or private company?

YES	NO

If YES, fill up the table below. Use additional pages if necessary.

Name of government agency/ company	Name of the Project	Reason for suspension/ blacklisting	Status (On-going/ Completed)

4. Has there ever been any project of your company in the University of the Philippines that was terminated by Administration?

YES	NO	NA

If YES, fill up the table below. Use additional pages if necessary.

Constituent University/UP Campus	Name of the Project	Reason for suspension/ blacklisting	Status (On-going/ Completed)

5. Do you certify that all the documents submitted by your Company and personnel are authentic?

YES	NO

6. Is there any pending investigation and/or case filed against your Company or your personnel in any court or any similar institution in relation to any government contracts awarded to your company? In relation to practice of profession of any of your personnel?

YES	NO

If YES, fill up the table below. Use additional pages if necessary.

For Company

Case Filed	Where Filed	Date Filed	Status (On-going/ Completed)	Remarks

For Personnel

Case Filed	Where Filed	Date Filed	Status (On-going/ Completed)	Remarks

I hereby certify that all statements and information provided herein are complete, true and correct.

Name & Signature of Bidder : _____
Authorized Representative : _____
Official Designation : _____
Company : _____
Date : _____

ACKNOWLEDGEMENT

SUBSCRIBED AND SWORN TO before me this _____ day of _____, 20__, affiant exhibited to me his/her Community Tax Certificate No. _____ issued on _____ at _____, Philippines.

Notary Public
Until 31 December 20___
PTR No.: _____
Issued at: _____
Issued on: _____
TIN: _____

tandard Form Number: SF-GOOD-13a
University of the Philippines Manila/Philippine General Hospital

Project Reference No.
Name of Project:
Location of Project:

Statement of All On-Going Government and Private Contracts

Including Contracts Awarded But Not Yet Started

BusinessName:_____
BusinessAddress_____

Name of Contract/ Project Cost	a. Owner's Name b. Address c. Telephone Nos.	Nature of Work	Bidder's Role		a. Date Awarded b. Date Started c. Date of Completion	% of accomplishment		Value of Outstanding Works/Undelivered Portion
			Description	%		Planned	Actual	
Government								
Private								

Total Cost

Note: This statement shall be supported with:
1. Notice of Award and/or Contract
2. Notice to Proceed issued by the owner

Submitted by : _____
(Printed Name & Signature)
Designation : _____
Date : _____

Standard Form Number: SF-GOOD-13a
University of the Philippines Manila/Philippine General Hospital

Project Reference No.
Name of Project:
Location of Project:

Statement of the Single Largest Completed Contract

Business Name: _____
Business Address: _____

Name of Contract	**a. Owner's Name b. Address c. Telephone Nos.**	**Nature of Work**	**Bidder's Role**		**a. Amount at Award b. Amount at Completion c. Duration**	**a. Date Awarded b. Contract Effectivity c. Date Completed**	
			Description	**%**			
Government							
Private							

Note: This statement shall be supported with:
1. Contract
2. Certificate of Completion
3. Certification of Acceptance

Submitted by : _____
(Printed Name & Signature)

Designation : _____
Date : _____

Sample Diagram for Bid Packaging



Sealing and Marking of Envelopes

ALL folders / envelopes shall be marked in accordance with Section 20.4 of the Instruction to Bidders in the Bidding Documents, which shall contain the following:

- Name of the contract to be bid in **CAPITAL LETTERS**;
-

SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES – AMPULES AND VIALS FOR CY2023 (FRAMEWORK AGREEMENT)

- Name and address of the prospective bidder in **CAPITAL LETTERS**;

- Be addressed to the Procuring Entity's BAC in accordance with ITB Clause 1.1;

BIDS AND AWARDS COMMITTEE (BAC) 1
UPM – PHILIPPINE GENERAL HOSPITAL
TAFT AVENUE, MANILA

- Bear the specific identification of this bidding process indicated in ITB Clause 1.2;

Project Reference No.: BAC1-2022-010-0068-A

Bear a warning "**DO NOT OPEN BEFORE**…" the date and time for the opening of bids, in accordance with ITB Clause 18

The color of the folders and envelopes to be used is Violet/ Purple